[go: up one dir, main page]

WO2025026857A1 - Methylation panel for cancer screening - Google Patents

Methylation panel for cancer screening Download PDF

Info

Publication number
WO2025026857A1
WO2025026857A1 PCT/EP2024/071082 EP2024071082W WO2025026857A1 WO 2025026857 A1 WO2025026857 A1 WO 2025026857A1 EP 2024071082 W EP2024071082 W EP 2024071082W WO 2025026857 A1 WO2025026857 A1 WO 2025026857A1
Authority
WO
WIPO (PCT)
Prior art keywords
methylation
cancer
polynucleotides
sample
dmp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2024/071082
Other languages
French (fr)
Inventor
Frauke LEENDERS
Petra Schneider
Matthias Siebert
Florian Lenz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics Products GmbH
Original Assignee
Siemens Healthcare Diagnostics Products GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siemens Healthcare Diagnostics Products GmbH filed Critical Siemens Healthcare Diagnostics Products GmbH
Publication of WO2025026857A1 publication Critical patent/WO2025026857A1/en
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/154Methylation markers

Definitions

  • the present invention relates to a combination of polynucleotides for the enrichment and/or detection of a panel of at least 4500 methylation sites in a sample comprising human DNA for cancer screening, wherein the methylation sites show a non-normal methylation pattern in at least one cancer training sample.
  • the invention further relates to a method of enriching DNA molecules derived from a subject’s sample comprising modifying the DNA molecules to allow for determination of the methylation status of methylation sites, contacting the converted molecules with a combination of polynucleotides selected from the combinations of polynucleotides binding to the methylation sites of the panel of the invention and enriching bisulfite-converted or enzymatically converted DNA molecules by hybridization capture.
  • BACKGROUND Cancer development is in many cases connected to a widespread change of DNA methylation in a cell.
  • DNA methylation is formed by the addition of a methyl group to the C5 position 202224094 2 of the cytosine ring in cytosine residues within a 5’- cytosine-phosphate-guanine-3’ (CpG) dinucleotide context in mammals.
  • CpG sites The majority of CpG sites is highly methylated in the genome with the exception of CpG islands (regions located in promoter regions) which are largely unmethylated.
  • genome-wide demethylation occurs during embryogenesis to form totipotent cells. This is followed by de novo methylation where tissue-specific genes undergo demethylation in their cell type of expression. DNA methylation is then maintained during DNA replication of somatic cells.
  • Cancer-associated changes typically include a hypermethylation of CpG islands, often spanning gene promoters and first exons.
  • TSG tumor suppressor genes
  • the promoter regions of oncogenes are often hypomethylated in tumor cells resulting in an activation of these genes.
  • Such epigenetic changes may occur early in tumorigenesis and are considered to be pervasive across a tumor type.
  • many cancers exhibit a high degree of concordance across tissues, or within the tissue of origin (Hoadley et al., 2018, Cell 173 (2), 291–304 e296).
  • Lung cancer is the leading cause of cancer-related death worldwide. Every year more people die globally from lung cancer than from prostate, breast and colon cancer combined (Stahel et al., 2019, European Society for Medical Oncology; Thoracic Tumours – Essentials for Clinicians). The disease prognosis can be improved if the tumor is detected at an early stage at which it can still be removed by surgical resection. Only 15 % of all lung cancers are 202224094 3 diagnosed at an early stage and 50 % of those will survive the next 5 years (Stahel et al., 2019).
  • Breast cancer which is the second-leading cause of cancer- related death of women in the United States (see https://www.cdc.gov/cancer/dcpc/research/update-on-cancer- deaths/) and other countries, is typically detected in screening approaches performed with imaging-based technologies such as mammography.
  • imaging-based technologies such as mammography.
  • abnormalities appearing in the initial mammography typically need to be clarified by additional examinations which can result in tissue biopsies.
  • a further problematic aspect of breast cancer screening by mammography is overdiagnosis (L ⁇ berg et al., 2015, Breast Cancer Research; 17:63). More than 61% of women are estimated to experience one false positive recall within an annual screening period over 10 years (Ho et al., 2022, JAMA Netw Open ;5(3):e222440).
  • the present invention addresses these needs and provides in a first aspect a combination of polynucleotides for the enrichment and/or detection of a panel of at least 4500 methylation sites in a sample comprising human DNA for cancer screening, wherein the methylation sites show a non-normal methylation pattern in at least one cancer training sample.
  • This combination of polynucleotides detects and/or enriches a panel of at least 4500 methylation sites in a sample comprising human DNA, which has been identified after intensive comparison and analysis efforts, in particular a complex statistical and bioinformatic assessment and which represents the optimized output of clinically relevant methylation sites, selected from a number of more than 28 million CpG loci or sites available in the human genome.
  • the panel as mentioned above was selected from over 450,000 methylation sites covered on the Illumina Infinium HumanMethylation450 BeadChip.
  • a discovery dataset comprising 95 and 68 matched tumor-normal samples for breast and non-small-cell lung cancer, respectively, was used.
  • methylation sites were selected based on a combined application of paired t-tests and fold change calculations to methylation levels quantified as m-values which are approximately homoscedastic and, therefore, statistically more valid for the differential analysis of methylation levels.
  • the accordingly selected sites were additionally enriched with sites localized within or nearby mRNA and 202224094 5 lncRNA genes that have been reported in the literature to provide a diagnostic, prognostic and/or predictive conclusion with respect to the presence of a cancer disease, in particular a breast or lung cancer.
  • CpG sites with discriminative methylation levels in tumor- and normal cohorts firstly a statistical hypothesis testing, based on paired t-tests followed by a correction for false discovery rate, was performed which allowed to identify CpG sites with significantly different mean methylation levels in the tested groups. Subsequently, for all CpG sites, computation of the fold change (FC) of mean methylation levels in the two groups was performed. Finally, CpG sites with high significance, i.e., a small p-value obtained in the first step as described above, which also show a large FC in their mean methylation levels obtained in the second step as defined above, were selected. For this purpose, appropriate thresholds for p-values and the FC were applied.
  • the combination of polynucleotides according to the present invention provides several advantages in comparison to screening approaches of the prior art. Firstly, it is capable of binding to a medium number of markers, i.e., methylation sites, which can be employed for enrichment of sample sequences and thereby reduces sequencing and analysis costs and at the same time allows for an increase of the sequencing depth. Secondly, in comparison to other small size solutions which only analyze up to 10 markers by qPCR, the combination of polynucleotides of the present invention drastically increases the number of features and thus improves the discriminative power of a classifier.
  • markers i.e., methylation sites
  • said significantly increased number of markers, including correlated markers, 202224094 6 further allows for an improved statistic or bioinformation assessment and thus reduces prediction uncertainty.
  • said methylation sites are represented by nucleotide sequences in the human DNA and said polynucleotides are primers and/or probes designed to hybridize to said nucleotide sequences in the human DNA allowing for the enrichment and/or detection said methylation sites.
  • said non-normal methylation pattern is a differential methylation pattern, wherein methylated and/or unmethylated sites are present in a cancer training sample in comparison to a healthy sample.
  • the healthy sample is a tissue sample, preferably an FFPE tissue sample, spatially adjacent to the cancer training sample.
  • said differential methylation pattern is present at a CpG site.
  • each polynucleotide has a length of about 50 to 150 nucleotides, preferably of about 120 nucleotides.
  • the sample comprising human DNA is a liquid biopsy sample or a tissue biopsy sample. It is particularly preferred that the human DNA is a cfDNA molecule or a genomic DNA molecule.
  • the methylation sites are located in or cover a multitude of genomic regions, 202224094 7 preferably genomic regions wherein a non-normal methylation pattern in at least one cancer training sample is present. It is further preferred that the methylation sites show a non-normal methylation pattern in at least one breast or lung cancer training sample. It is further preferred that the one or more primers and/or probes are designed to cover one or more methylation sites. According to another preferred embodiment the polynucleotides are designed to enrich and/or detect at least 4500 differentially methylated positions (DMPs) selected from Table 1.
  • DMPs differentially methylated positions
  • the present invention relates to a method of enriching DNA molecules derived from a subject’s sample, preferably a liquid biopsy or tissue biopsy sample, comprising: (a) modifying the DNA molecules to allow for determination of the methylation status of methylation sites, preferably by bisulfite-conversion or enzymatic conversion; (b) contacting the converted molecules with a combination of polynucleotides selected from the combination of polynucleotides as defined herein and enriching bisulfite- converted or enzymatically converted DNA molecules by hybridization capture.
  • the enrichment method additionally comprises the step (c) of determining the sequence of the enriched molecule, thereby also determining the methylation status of the enriched molecule.
  • the present invention relates to a method of diagnosing, prognosing or predicting a cancer 202224094 8 disease in a subject, comprising: (a) enriching DNA molecules derived from the subject’s sample; and determining the sequence and methylation status of the enriched DNA molecules, preferably according to the method as defined herein; (b) assessing the obtained sequence information, preferably on the basis of a database comprising information on cancer related methylation states, more preferably via a bioinformatic analysis; and (c) deriving a diagnostic, prognostic and/or predictive conclusion with respect to the presence of a cancer disease in the subject.
  • the method additionally comprises the step of evaluation of: (i) the subject’s imaging-based data, preferably derived from a mammography analysis, an ultra-low-dose (ULD) CT screening, medical images and/or pathology images; and/or (ii) the subject’s non-imaging based data, such as data on age, sex, race, characteristics of cancer phenotype, histologic characteristics, stage of development of cancer, histologic subtype, detectable molecular changes, preferably on the level of the genome, transcriptome, metabolome, proteome, glycome or lipidome, biomarkers and/or laboratory tests, wherein the results of the evaluation(s) contribute to the diagnostic, prognostic and/or predictive conclusion with respect to the presence of a cancer disease in the subject.
  • imaging-based data preferably derived from a mammography analysis, an ultra-low-dose (ULD) CT screening, medical images and/or pathology images
  • non-imaging based data such as data on age, sex, race, characteristics of
  • FIG. 1 shows a schematic illustration depicting the steps which led to the identification of the panel for cancer screening according to the present invention.
  • TCGA Cancer Genome Atlas
  • FIG. 2 shows a further schematic illustration of an embodiment of the invention, namely the steps of a diagnostic/prognostic method according to the invention. Based on the task to screen a subject for the presence of a cancer disease or the likelihood to develop a cancer disease (10), different steps can be performed.
  • One important step is the performance of an analysis of a subject's sample obtained in a minimal invasive blood test comprising the determination of the methylation status of the methylation sites of the panel for cancer screening of the present invention (11) and thus provides a first diagnostic/prognostic conclusion on the presence of a cancer disease or the likelihood of developing a cancer disease.
  • parallel step imaging-based screening data of the subject which has been obtained, e.g., with ULD CT screening or mammography, is analyzed (12) contributing to the diagnostic/prognostic conclusion on the presence of a cancer disease or the likelihood of developing a cancer disease.
  • non-imaging-based data e.g., obtained from protein screens or the like, is analyzed (13) further contributing to the diagnostic/prognostic conclusion on the presence of a cancer disease or the likelihood of developing a cancer disease.
  • the combination of the results (14) allows for a summary conclusion on the presence of a cancer disease or the likelihood of developing a cancer disease.
  • the present invention concerns in one aspect a combination of polynucleotides for the enrichment and/or detection of a panel of at least 4500 methylation sites in a sample comprising human DNA for cancer screening, wherein the methylation sites show a non-normal methylation pattern in at least one cancer training sample.
  • the term "combination of polynucleotides" as used herein refers to groupings of polynucleotides which can be provided in different forms.
  • the combination of polynucleotides may be provided in the form of a liquid-phase reagent or a set of reagents.
  • the reagent or set of reagents may comprise the polynucleotides in dissolved or soluble state.
  • the reagent, reagents or set of reagents may be provided as liquid or in a dried from, e.g. freeze-dried.
  • the reagent or set of reagents may accordingly be provided or optimized for resuspension.
  • methylation sites as used herein relates to the specific sites in a genomic sequence which are modified by the addition of a methyl group to a cytosine which is converted to a 5-methylcytosine, or, in certain situations, the removal of a methyl group from the 5-methylcytosine.
  • the methylation of DNA is a form of epigenetic modification which has the capability of altering the expression of genes and other elements and may accordingly have an effect on, e.g., silencing of tumor suppressor genes and/or increasing the expression of oncogenes, etc., thus potentially contributing to the development of a cancer disease in a subject.
  • the methylation site is a 5’-cytosine-phosphate- guanine-3’ (CpG) dinucleotide site.
  • the methylation sites are typically distributed throughout the genome and not confined to expressed genes. In many cases, methylation sites are 202224094 13 located in promoter or regulatory regions.
  • the analysis of the methylation status at certain methylation sites as defined herein is based on specific techniques for the detection of methyl groups.
  • DNA molecules to be analyzed for the presence of their methylation status are specifically processed to preserve the methylation status information.
  • Such processing may be based on techniques such as bisulfite conversion or enzymatic conversion.
  • the "bisulfite conversion” comprises the treatment of DNA molecules with bisulfite which converts cytosine to uracil but does not convert 5-methylcytosines.
  • Subsequent amplification, which turns uracil to thymine, is usually carried out using PCR or methylation-specific PCR (MSP).
  • uracil is recognized as thymine and the opposite strand is filled in with adenine due to complementary base pairing, while cytosines are paired with guanines in bisulfite-untreated stretches.
  • enzymatic conversion instead of a chemical conversion of unmethylated cytosines an enzymatic conversion is performed. Typically, a set of two enzymes is used.
  • the enzymes TET2 and T4-BGT are used to convert 5-methylcytosines into products that cannot be deaminated by the enzyme APOBEC.
  • the enzyme APOBEC deaminates unmodified cytosines by converting them to uracils. Further analysis steps correspond to the bisulfite approach described above.
  • non-normal methylation pattern as used in the context of the present invention relates to the methylation of a multitude of methylation sites as defined herein, 202224094 14 wherein said methylation does not occur in "normal" tissues or samples, e.g., tissues or samples derived from healthy subjects, preferably subjects not afflicted by a cancer disease, more preferably subjects not afflicted by a lung cancer or subjects not afflicted by a breast cancer. Instead said methylation occurs in at least one cancer training sample.
  • a non-normal methylation pattern may also be given in case said methylation occurs in "normal" tissues or samples, e.g., tissues or samples derived from healthy subjects, preferably subjects not afflicted by a cancer disease, more preferably subjects not afflicted by a lung cancer or subjects not afflicted by a breast cancer, whereas said methylation does not occur in at least one cancer training sample.
  • normal tissues which are understood in the context of the present invention as "healthy" samples may preferably be derived from a tissue sample which was obtained from a normal zone spatially adjacent to a cancer training sample.
  • cancer samples may be or may have been obtained or removed from the body by means of a biopsy.
  • tissue is accompanied and, during the analysis, is also compared with spatially adjacent "normal tissue” or "healthy tissue", i.e., from a normal zone.
  • tissues healthy and cancerous, are preferably FFPE (formalin-fixed paraffin- embedded) tissues obtained by biopsy.
  • FFPE formalin-fixed paraffin- embedded
  • cancer diseases or corresponding medical conditions include a stomach, colon, rectal, liver, pancreatic, lung, breast, cervix uteri, corpus uteri, ovary, prostate, testis, bladder, renal, brain/CNS, head and neck, or throat cancer, Hodgkin's disease, non- Hodgkin's lymphoma, multiple myeloma, leukemia, melanoma skin 202224094 15 cancer, non-melanoma skin cancer, acute lymphocytic leukemia, acute myelogenous leukemia, Ewing's sarcoma, small cell lung cancer, choriocarcinoma, rhabdomyosarcoma, Wilms' tumor, neuroblastoma, hairy cell leukemia, mouth/pharynx, esophagus, larynx, kidney cancer, lymphoma, or any subtype thereof.
  • the cancer disease is a lung cancer or a breast cancer. Further, the cancer disease may further include the presence of pre-invasive lesions or a pre- cancerous cell population, or a predisposition for cancer or tumor which is reflected by the presence of certain DNA methylation patterns as enshrined in the DMPs of the panel of the present invention.
  • the term "cancer training sample” relates to a sample for which independent information on the affliction by a cancer disease has been obtained, i.e., the cancerous status has been confirmed, e.g., by histological or molecule analysis. It is preferred that the cancer training sample is a lung cancer sample (lung cancer training sample) or a breast cancer sample (breast cancer training sample).
  • the present invention further envisages the analysis or derivation of information not only from one cancer training sample, but form a larger number of training samples, e.g., 5, 10, 15, 20, 25, 50, 100, 500, 1000 or more or any number in between the mentioned numbers.
  • the group of cancer training samples may, in certain embodiments may be derived from identical cancer types, e.g., lung or breast cancer.
  • the present invention also envisages a mixture of cancer types, e.g., a mixture of lung and breast cancer types.
  • Information on the methylation status of the cancer training samples may, in certain embodiments, be derivable from data repositories or databases, or may, in certain embodiments, be provided de novo.
  • a non-normal methylation pattern within the context of the present invention may thus be based on the presence of a differentially methylated position (DMP), which shows a methylation status variation in a normal tissue vs. a tissue derived from a subject afflicted by a cancer disease, e.g., a subject afflicted by a lung cancer or a subject afflicted by a breast cancer.
  • DMP differentially methylated position
  • the non-normal methylation pattern is a differential methylation pattern, wherein typically methylated sites are present in a cancer training sample in comparison to a healthy sample.
  • the differential methylation pattern underlying the present invention and enshrined in the DMPs of Table 1 is hence not restricted to a methylated cancerous vs. unmethylated non-cancerous pattern, but merely reflects any registered different methylation situation (methylated or unmethylated) in a comparison of the cancer training sample vs. the healthy sample.
  • the panel of at least 4500 methylation sites in a sample comprising human DNA according to the present invention is capable of distinguishing a cancerous target subject's sample from a non-cancerous.
  • the panel may comprise at least 4500, or at least 4550 or all 4556 different DMPs, or any number of DMPs in between the mentioned numbers, e.g., of the DMPs of Table 1.
  • the methylation sites reflected by the panel as described herein or DMPs covered by the panel are located in more than one genomic location, preferably in a multitude of genomic locations.
  • the methylation sites may be located on different 202224094 17 chromosomes, different chromosomal arms, etc.
  • the DMPs of Table 1 or a subset thereof may accordingly cover regions on all human chromosomes, or 90%, 80%, 70%, 60%, 50%, 40% or 30% of the human chromosomes.
  • a selection of chromosome-based DMPs according to project needs and diagnostic purposes is further envisaged by the present invention.
  • a selection and grouping of such DMPs e.g., of the DMPs of Table 1, is easily implementable with the Illumina ID system and, for example, its connection to genomic browsers or other suitable bioinformatic tools.
  • the differential methylation status may be determined on a larger scale, e.g., on the basis of regional or chromosomal methylation states. It is envisaged that the genomic regions selected are those in which a non-normal methylation pattern in at least one cancer training sample is present.
  • the present invention further envisages the use of the concept of differentially methylated regions (DMRs), which reflect a summary or average regional methylation status in a larger section of a genome, e.g., 1 kb, 2 kb, 3 kb, 10 kb, 20 kb, 50 kb, 100 kb, 500 kb or more or any value in between the mentioned values.
  • DMRs differentially methylated regions
  • the status may be "methylated” if 50% or more of the CpG sites or DMPs (e.g., the DMPs as mentioned in Table 1 or a subset thereof) in the region are methylated and "unmethylated” if less than 50% of the CpG sites in the region are methylated.
  • the regional DNA methylation status may be a composite methylation status, with the average methylation status as defined above as one possible characteristic.
  • Further elements of the composite methylation status may include the methylation status of known genomic elements, e.g., CpG islands, genes, gene promoters, enhancers, transcription factor binding sites, including extensions to said sections, e.g., within 1 kb around transcription start site etc.
  • the regional DNA methylation status may accordingly be defined with respect to known genomic elements, e.g., CpG islands, genes, gene promoters, enhancers, transcription factor binding sites, including extensions to said sections, e.g., within 1 kb around transcription start site etc.
  • the regional DNA methylation status may correspond to the mean methylation levels of all CpG sites in a region.
  • Information on DMRs may accordingly be for additional diagnostic, prognostic or predictive assessment activities.
  • the DMPs at least comprised in the methylation site panel are the DMPs listed in Table 1 or a sub-section thereof.
  • the panel comprises a medium number of DMPs, e.g., at least 4500 or all 4556 DMPs of the DMPs mentioned in Table 1.
  • the panel comprises at least all DMPs mentioned in Table 1.
  • the panel may, in addition to the DMPs of Table 1, comprise further DMPs, e.g., obtained from further studies or future analysis.
  • the panel may comprise a subset of the DMPs of Table 1, e.g. a feature which allows for an adaptation of the selection of the DMPs to a target subject or patient, or a subset as reflected by the above indicated numbers of DMPs.
  • the subset of DMPs of Table 1 may be associated with lung cancer, or the subset DMPs of Table 1 may be associated with breast cancer.
  • the definition or selection of a corresponding sub-set of DMPs of Table 1 may be based on additional scientific evidence, e.g., as published or derivable from suitable databases as described herein. 202224094 19 Table 1 DMPs according to the invention. No. DMP ID No. DMP ID No. DMP ID No. DMP ID No. DMP ID No. DMP ID No. DMP ID No. DMP ID No. DMP ID No. DMP ID No. DMP ID No. DMP ID No. DMP ID No. DMP ID No. DMP ID No. DMP ID No. DMP ID No. DMP ID
  • DMP ID No. DMP ID 1 cg00001747 761 cg08884571 1521 cg17863743 2281 cg27122213 3041 cg25982483 3801 cg21816532 2 cg00002719 762 cg08892613 1522 cg17911318 2282 cg27130240 3042 cg26019112 3802 cg22583148 3 cg00003298 763 cg08893692 1523 cg17919004 2283 cg27170427 3043 cg26024530 3803 cg23217463 4 cg00012529 764 cg08901662 1524 cg17922359 2284 cg27179533 3044 cg26059468 3804 cg24889708 5 cg00017437 765 cg08934846 1525 cg17939040 2285 cg27189087 3045 cg26074603 38
  • DMP ID No. DMP ID No. DMP ID No. DMP ID No. DMP ID No. DMP ID No. DMP ID No. DMP ID 40 cg00515457 800 cg09432775 1560 cg18249173 2320 cg27655158 3080 cg27058257 3840 cg00639517 41 cg00552087 801 cg09434193 1561 cg18249580 2321 cg27663938 3081 cg27131891 3841 cg00904483 42 cg00557947 802 cg09442654 1562 cg18249634 2322 cg00001583 3082 cg27170782 3842 cg00981003 43 cg00582524 803 cg09465698 1563 cg18250028 2323 cg00028935 3083 cg27177554 3843 cg01204683 44 cg0058
  • Information on the genomic location of the methylation sites, as well as data on associated experiments, studies and scientific references etc. can be derived, for example, from the website of Illumina (www.illumina.com). Accordingly, the identity of each DMP represented by each DMP loci identifier as depicted in Table 1 is publicly available from the Illumina website, e.g., under reference to the DMP sites used in the Infinium HumanMethylation450 BeadChip kit.
  • references may be downloaded at https://webdata.illumina.com/downloads/ productfiles/humanmethylation450/humanmethylation450_15017482 _v1-2.csv.
  • a genome browser such as, for example, the genome browser of USCS (http://genome- euro.ucsc.edu/), which provides a graphic scheme of the genomic location including additional information on the encoded sequences etc. can be used to derive molecular and positioning information on most DMP loci identifier as depicted in Table 1. For instance, upon introducing the DMP's Illumina ID as shown in Table 1 (cg%) into the genome browser coordinates of the genomic location of the DMP can be retrieved.
  • Coordinates of genomic location of the DMPs may accordingly be used for the design and synthesis of adjacent or binding polynucleotides, e.g., primer sequences, or for sequence analysis purposes etc.
  • the Illumina ID nomenclature is constructed on CG loci designation which is based on actual or contextual sequences of each CpG locus and takes advantage of the sequences flanking the DMP. Thereby the ID is unaffected by reference genome changes or differences in genome versions. This allows for an unambiguous assignment of the ID to genomic coordinates.
  • the Illumina Infinium HumanMethylation450 BeadChip array system (or any future and functionally equivalent variant thereof) may be used to further analyze or assess any of the DMPs shown in Table 1.
  • the combination of polynucleotides according to the present invention is for the enrichment and/or detection of the panel of at least 4500 methylation sites as defined above in a 202224094 38 sample comprising human DNA for cancer screening, i.e., it allows to select or enrich DNA molecules, e.g., DNA sample fragments and analyze them with respect to the presence of methylated CpG sites, indicating the presence of a cancer disease or a predisposition for a cancer disease, preferably of lung or breast cancer.
  • a cancer disease e.g., a predisposition for a cancer disease, preferably of lung or breast cancer.
  • the combination of polynucleotides is represented by nucleotide sequences in the human DNA.
  • the polynucleotides may be primers and/or probes designed to hybridize to said nucleotide sequences in the human DNA allowing for the enrichment and/or detection of said methylation sites.
  • the term "represented by nucleotide sequences" as used herein means that the DMP itself is localized or embedded in a genomic context in the form of adjacent sequences at the 5' and 3' end. These contextual sequences, together with the genomic coordinate, represent the methylation site and allow for the provision of complementary polynucleotides, e.g., in the form of polynucleotide probes.
  • complementary polynucleotides or polynucleotide probes may, for example, be capable of hybridizing to the nucleotide sequence representing the DMP.
  • complementary polynucleotides may be capable of hybridizing not only to contextual sequences of one DMP, but also to such sequences of two or more DMPs, e.g., in case DMPs are located in close vicinity.
  • the complementary polynucleotides are primers and/or probes and may be used for enrichment procedures and/or detection of said methylation sites, e.g., 202224094 39 by allowing for a binding or hybridization with a human DNA molecule from a target subject's or patient's sample.
  • subject refers to several different groups of individuals such as a healthy individual that is not suspected of having a pre-invasive lesion, a pre- cancerous cell or a cancer disease; or an individual that is suspected of having a pre-invasive lesion or a pre-cancerous cell; or an individual, that has a pre-invasive lesion or a pre-cancerous cell population but is not suspected of having a cancer disease; or an individual that has a pre-invasive lesion or a pre-cancerous cell population and is suspected of having a cancer disease; or an individual that is suspected of having a pre-invasive lesion or a pre-cancerous cell population; or an individual that has a pre-invasive lesion or a pre-cancerous cell population; or an individual that is suspected of having a cancer disease; or an individual that has a cancer disease.
  • a “target subject” is any subject as defined above, for which an analysis based on the methods described herein is considered suitable, diagnostically useful, or necessary.
  • the term "patient” as used herein is meant to relate to a sub-group of the subjects as defined herein, i.e., an individual that has a pre-invasive lesion or a pre-cancerous cell population; or an individual that is afflicted by a cancer disease.
  • the enrichment is based on a hybridization of the combination of polynucleotides according to the present invention, e.g.
  • the human DNA molecule to be enriched may be a non-modified DNA molecule or a modified DNA molecule, e.g., as described herein, preferably a DNA molecule which has been bisulfite- converted or enzymatically converted.
  • the combination of polynucleotides may, in certain embodiments, be linked or tethered to a solid support such as an array structure or the like. Also, a link, e.g., via biotin-streptavidin interaction, with magnetic beads and a corresponding actuation and fixation by magnetic forces is envisaged.
  • the combination of polynucleotides may be provided in the form of a solid-phase reagent or as a solid phase means, or a set of such means.
  • the solid-phase reagent or means may accordingly comprise the polynucleotides as defined herein bound to a solid phase.
  • the solid phase may be or comprise a particle or set of particles or be associated to or presented as an array.
  • the polynucleotides may have any suitable length. Preferably, they comprise 50 to 150 nucleotides, e.g., 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 nucleotides, or any value in between the mentioned values. In particularly preferred embodiments, they have a length of about 120 nucleotides. It is further preferred that the polynucleotides are designed to hybridize to human DNA molecules comprising more than one DMP, e.g., two or three or more. For example, the polynucleotides may be designed to cover an optimized amount of DMPs as shown in Table 1.
  • At least 4500 DMPs or the entire set of DMPs of Table 1 may be represented by a number of about 3000, 4000 or 202224094 41 4500 polynucleotides, or any other suitable number.
  • the present invention also envisages a lower number of probes, e.g., if more than one DMP is covered by a polynucleotide. Also envisaged is a higher number of oligonucleotides, e.g., if a different target coverage is intended, or if additional DMPs not mentioned in Table 1 are further included.
  • the present invention also envisages the use of a panel as defined herein, preferably a panel comprising the DMPs of Table 1 or at least 4500 DMPs thereof, for the selection, provision, design, synthesis and/or modification of a combination of complementary polynucleotides as defined herein.
  • the human DNA molecule for subsequent analysis, in particular enrichment may be derived from a target subject's or patient's sample.
  • the sample may be any suitable sample type or form.
  • the sample may, for example, have been obtained from a subject or group of subjects.
  • the sample is a tumor sample, i.e., the nucleic acids may be extracted from a tumor of a subject, in other embodiments the sample may be a tissue, e.g., tissue biopsy, urine, blood, semen, liquor, plasma, serum or other sample. Particularly preferred are liquid biopsy samples derived from blood/urine or other body fluids or tissue biopsy samples. Also envisaged is to make use of previously deposited samples. It is particularly preferred that the sample is a cell free DNA (cfDNA) sample.
  • cfDNA cell free DNA
  • cfDNA refers to degraded DNA fragments released to body fluids such as blood plasma, urine, cerebrospinal fluid, etc., wherein the cfDNA typically has a short half-life and requires rapid processing and/or stabilization.
  • the typical size of cfDNA fragments is about 165 bp.
  • cfDNA comprises various forms of DNA freely 202224094 42 circulating in body fluids such as circulating tumor DNA (ctDNA) or cell-free mitochondrial DNA (cf mtDNA).
  • ctDNA circulating tumor DNA
  • cf mtDNA cell-free mitochondrial DNA
  • the sample is a genomic human DNA molecule sample, which can be derived, e.g., from a tissue obtained in a biopsy.
  • the present invention relates to a method of enriching DNA molecules derived from a subject’s sample, e.g., as described above comprising: (a) modifying the DNA molecules to allow for determination of the methylation status of methylation sites; (b) contacting the converted molecules, i.e. the bisulfite-converted or enzymatically converted molecules, with a combination of polynucleotides as described herein and enriching bisulfite-converted or enzymatically converted DNA molecules by hybridization capture.
  • the "modification of DNA molecules” may be based on any technology, which allows for the determination of the methylation status of methylation sites. It is preferred that the modification is a bisulfite-conversion or enzymatic conversion as described in detail herein.
  • the "contacting" of correspondingly modified DNA molecules with polynucleotides is to be understood as binding or hybridization reaction with complementary sequences, preferably polynucleotide probes as described herein.
  • the binding is a sequence-specific hybridization, which allows to specifically collect only DNA molecules which show a high degree of complementarity with the polynucleotides, e.g., 95%, 96%, 97%, 98%, 99%, 100%.
  • the binding specificity may be adjusted by changes to the hybridization conditions, e.g., temperature, pH, ionic concentrations etc.
  • the polynucleotides may have any suitable length, preferably a length of 50–150 nucleotides, more preferably of 120 nucleotides.
  • the polynucleotides may be 202224094 43 free floating or be tethered or linked to a support, e.g., as described herein in detail, to allow for pulling down binding DNA molecules.
  • the alternative use of magnetic beads and a corresponding magnetic actuation approach is envisaged. Further contemplated are antibody-based techniques, as well as molecular approaches based on biotin/streptavidin interactions.
  • the bound DNA molecules are "enriched", i.e., only DNA molecules which are in fact specifically bound to the polynucleotide probes are kept or retained, whereas other, non-bound or not specifically bound DNA molecules or other components in a mixture are discarded.
  • the enriched DNA molecules may be used for further analysis steps or stored for future activities.
  • Enriched DNA molecules may, in additional embodiments, further be amplified. Also contemplated is a spiking with specific indices that allow for a sequencing of the molecules.
  • the method comprises a step of determining the sequence of the enriched molecule.
  • the sequence data of the enriched and optionally previously modified DNA molecules may be obtained with any suitable technology, preferably in a high-throughput approach.
  • This typically includes next-generation sequence (NGS) or second-generation sequencing techniques.
  • NGS next-generation sequence
  • Such approaches comprise any sequencing method that determines the nucleotide sequence of either individual nucleic acid molecules or expanded clones for individual nucleic acid molecules in a highly parallel fashion.
  • the sequencing may be performed according to any suitable massive parallel approach.
  • Typical platforms include Illumina, Life Technologies Ion Proton, Oxford Nanopore Technologies, Pac Bio, Complete Genomics/BGI, Ultima, Element Biosciences, 202224094 44 Singular Genomics, GeneReader, GenapSys, Solexa, Solid or Helicos Biosciences Heliscope systems.
  • the sequencing may include a previous preparation of nucleic acids, the sequencing, as well as subsequent imaging and initial data analysis steps.
  • Preparation steps may, for example, include amplification steps, e.g., PCR amplification, randomly breaking nucleic acids into smaller sizes and generating sequencing templates such as fragment templates.
  • Spatially separated templates can, for example, be attached or immobilized at solid surfaces which allows for multiple sequencing reactions to be performed simultaneously.
  • a library of nucleic acid fragments may be generated and adaptors containing universal priming sites may be ligated to the end of the fragments. Subsequently, the fragments can be denatured into single strands and captured by beads.
  • Suitable sequencing methods include, but are not limited to, cyclic reversible termination (CRT) or sequencing by synthesis (SBS) by Illumina, sequencing by ligation (SBL), single-molecule addition (pyrosequencing) or real-time sequencing.
  • CRT cyclic reversible termination
  • SBS sequencing by synthesis
  • SBL sequencing by ligation
  • pyrosequencing single-molecule addition
  • Exemplary platforms using CRT methods are Illumina/Solexa and HelicoScope.
  • Exemplary SBL platforms include the Life/APG/SOLiD support oligonucleotide ligation detection.
  • An exemplary pyrosequencing platform is Roche/454.
  • Exemplary real-time sequencing platforms include the Pacific Biosciences platform and the Life/Visi-Gen platform.
  • sequencing methods to obtain massively parallel nucleic acid sequence data include nanopore sequencing, sequencing by hybridization, nano-transistor array-based sequencing, scanning tunneling microscopy (STM) based sequencing, or nanowire-molecule sensor-based sequencing. Further details with respect to the sequencing approach would be known to the skilled person or can be derived from suitable literature 202224094 45 sources such as Goodwin et al., Nature Reviews Genetics, 2016, 17, 333-351, or van Dijk et al., Trends in Genetics, 2014, 9, 418-426. Correspondingly obtained data are provided in the form of sequencing reads which may be single-end or paired-end reads. Obtaining such sequencing data may further include the addition of assessment steps or data analysis steps.
  • sequencing reads of a length of about 50 to about 170, e.g., 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170 or more nucleotides or any value in between the mentioned values.
  • Particularly preferred is paired end sequencing with 2 x 75 bp reads or with 2 x 150 bp reads.
  • the obtained sequence data may further be assembled into contigs or suitable subsections thereof, e.g., on the basis of chromosomes, chromosome portions etc., and/or be aligned to a reference sequence, e.g., an annotated genomic sequence.
  • the alignment and comparison step further includes a reference searching step of literature knowledge concerning identified mutations or aberrations as well as associated cancer diagnostic information.
  • the elucidation of the sequence of the enriched DNA molecules further allows to determine the methylation status of the enriched molecule. For example, as described above, in the DNA sequencing, uracil, which is turned to thymine during amplification, is recognized as thymine during sequencing and on the opposite strand adenine is provided due to base pairing, while methylated cytidines are paired with guanines.
  • C->U transitions at the unmethylated sites can accordingly be 202224094 46 detected, e.g., by comparing the sequences with reference sequences or, for example, parallel sequencing results with enriched non-bisulfite converted or non-enzymatic converted DNA molecules.
  • the present invention envisages a double or parallel approach wherein DNA molecules from a sample are (i) modified by the bisulfite or enzymatic conversion; and (e.g., a portion of the sample) (ii) are not modified. Both groups of molecules are subsequently enriched and analyzed as described above, e.g., by determining the sequence. Finally, a comparison of both sequences may be performed to detect methylated positions.
  • the present invention relates to a method of diagnosing, prognosing or predicting a cancer disease in a subject.
  • the method comprises a step of enriching DNA molecules derived from the subject’s sample and determining the sequence and methylation status of the enriched DNA molecules.
  • the enrichment is preferably performed according to the methods as described herein.
  • a target subject's sample is obtained, or such a sample is used for enrichment, preferably using the combination of polynucleotides as described herein.
  • the sequence and/or methylation status of the enriched DNA molecules is determined, as described herein. 202224094 47
  • the obtained sequence information and methylation status information is analyzed. This is preferably done with the help of or by using a database comprising information on cancer related methylation states. It is particularly preferred to use bioinformatic analysis procedures.
  • diagnostic, prognostic and/or predictive conclusion refers to information on medical or therapeutic consequences of non- normal methylation pattern detected in the analyzed DNA molecules.
  • a certain methylation status of a DMP preferably of a multitude of DMPs, covered by a DNA molecule or a group of DNA molecules or the majority of DNA molecules, preferably of enriched DNA molecules of a target subject's sample is identified which is connected to cancer training samples, e.g., a lung or breast cancer training sample
  • this connection or link may be translated into a diagnostic output, e.g. a classification as carcinogenic, preferably for lung or breast cancer.
  • connection or link may be translated into a prognostic output, e.g., reflected by a classification as potentially carcinogenic or carcinogenic in an early stage or the like, e.g., early-stage lung or breast cancer.
  • this connection or link may be translated into a predictive output, e.g., reflected by a corresponding classification.
  • Corresponding information may, for example, be derived from suitable literature sources or database entries associated with the DNA methylation data and therapeutic suggestions or options.
  • the diagnostic, prognostic and/or predictive conclusion with respect to the presence of a cancer disease in the subject may additionally be based on further data.
  • Such further data may, for example, be the subject’s imaging-based data.
  • contemplated imaging-based data are mammography analysis data, ultra-low- dose CT screening data, medical images and/or pathology images.
  • These data which preferably are themselves already connected to or translated into a diagnostic, prognostic or predictive output may be offset or combined with the conclusions derived from the differential methylation analysis.
  • These data may in principle be combined with conclusions and other data entities via multimodal data integration. Typically, the integration may be performed as early, intermediate or late fusion.
  • the present invention preferably contemplates a late fusion in which, for example, a methylation-based score is combined with an imaging-based score, e.g., using a logistic regression. Also envisaged are early and intermediate fusion approaches.
  • the combination of input data may, based on suitable weighing algorithms, result in an overall diagnostic, prognostic and/or predictive conclusion.
  • the diagnostic, prognostic and/or predictive conclusion with respect to the presence of a 202224094 49 cancer disease in the subject may additionally be founded on non-imaging-based data.
  • contemplated non-imaging- based data are data on age, sex, race, characteristics of cancer phenotype, histologic characteristics, stage of development of cancer, histologic subtype, detectable molecular changes, preferably on the level of the genome, transcriptome, metabolome, proteome, glycome or lipidome, biomarkers and/or laboratory tests. These data may be offset or combined with the conclusions derived from the differential methylation analysis and optionally with the conclusions including the imaging-based data. These data may in principle be combined with conclusions and other data entities via multimodal data integration as defined herein above. In specific embodiments, the combination input data may, based on suitable weighing algorithms, result in a further, more complete overall diagnostic, prognostic and/or predictive conclusion. Corresponding information, e.g., regarding the influence of these factors on disease manifestations etc. may, for example, be derived from suitable literature sources or database entries associated with the methylation data, e.g., non-normal methylation patterns.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to a combination of polynucleotides for the enrichment and/ or detection of a panel of at least 4500 methylation sites in a sample comprising human DNA for cancer screening, wherein the methylation sites show a non-normal methylation pattern in at least one cancer training sample. The invention further relates to a method of enriching DNA molecules derived from a subject' s sample comprising modifying the DNA molecules to allow for determination of the methylation status of methylation sites, contacting the converted molecules with a combination of polynucleotides selected from the combinations of polynucleotides binding to the methylation sites of the panel of the invention and enriching bisulfite-converted or enzymatically converted DNA molecules by hybridization capture. Also envisaged is a corresponding method of diagnosing, prognosing or predicting a cancer disease in a subject, comprising enriching DNA molecules derived from the subject' s sample, determining the sequence and methylation status of the enriched DNA molecules, assessing the obtained sequence information; and deriving a diagnostic, prognostic and/or predictive conclusion with respect to the presence of a cancer disease in the subject.

Description

202224094 1 DESCRIPTION Methylation panel for cancer screening TECHNICAL FIELD The present invention relates to a combination of polynucleotides for the enrichment and/or detection of a panel of at least 4500 methylation sites in a sample comprising human DNA for cancer screening, wherein the methylation sites show a non-normal methylation pattern in at least one cancer training sample. The invention further relates to a method of enriching DNA molecules derived from a subject’s sample comprising modifying the DNA molecules to allow for determination of the methylation status of methylation sites, contacting the converted molecules with a combination of polynucleotides selected from the combinations of polynucleotides binding to the methylation sites of the panel of the invention and enriching bisulfite-converted or enzymatically converted DNA molecules by hybridization capture. Also envisaged is a corresponding method of diagnosing, prognosing or predicting a cancer disease in a subject, comprising enriching DNA molecules derived from the subject’s sample, determining the sequence and methylation status of the enriched DNA molecules, assessing the obtained sequence information; and deriving a diagnostic, prognostic and/or predictive conclusion with respect to the presence of a cancer disease in the subject. BACKGROUND Cancer development is in many cases connected to a widespread change of DNA methylation in a cell. DNA methylation is formed by the addition of a methyl group to the C5 position 202224094 2 of the cytosine ring in cytosine residues within a 5’- cytosine-phosphate-guanine-3’ (CpG) dinucleotide context in mammals. The majority of CpG sites is highly methylated in the genome with the exception of CpG islands (regions located in promoter regions) which are largely unmethylated. Typically, genome-wide demethylation occurs during embryogenesis to form totipotent cells. This is followed by de novo methylation where tissue-specific genes undergo demethylation in their cell type of expression. DNA methylation is then maintained during DNA replication of somatic cells. Cancer-associated changes typically include a hypermethylation of CpG islands, often spanning gene promoters and first exons. In cancer cells, the promoters of tumor suppressor genes (TSG) are often hypermethylated which is associated with silencing of these TSGs. The promoter regions of oncogenes are often hypomethylated in tumor cells resulting in an activation of these genes. Such epigenetic changes may occur early in tumorigenesis and are considered to be pervasive across a tumor type. Despite the complex nature of changes to the epigenetic situation many cancers exhibit a high degree of concordance across tissues, or within the tissue of origin (Hoadley et al., 2018, Cell 173 (2), 291–304 e296). Lung cancer is the leading cause of cancer-related death worldwide. Every year more people die globally from lung cancer than from prostate, breast and colon cancer combined (Stahel et al., 2019, European Society for Medical Oncology; Thoracic Tumours – Essentials for Clinicians). The disease prognosis can be improved if the tumor is detected at an early stage at which it can still be removed by surgical resection. Only 15 % of all lung cancers are 202224094 3 diagnosed at an early stage and 50 % of those will survive the next 5 years (Stahel et al., 2019). Breast cancer, which is the second-leading cause of cancer- related death of women in the United States (see https://www.cdc.gov/cancer/dcpc/research/update-on-cancer- deaths/) and other countries, is typically detected in screening approaches performed with imaging-based technologies such as mammography. However, abnormalities appearing in the initial mammography typically need to be clarified by additional examinations which can result in tissue biopsies. A further problematic aspect of breast cancer screening by mammography is overdiagnosis (Løberg et al., 2015, Breast Cancer Research; 17:63). More than 61% of women are estimated to experience one false positive recall within an annual screening period over 10 years (Ho et al., 2022, JAMA Netw Open ;5(3):e222440). Several screening approaches for early detection of cancer are currently investigated in clinical trials using targeted methylation signatures (Liu et al., 2020, Annals of Oncology; 2020; Vol 31;6;745-759). In one of these targeted methylation assays a wide range of genomic sites (interrogating approximately 1 million informative CpG sites) is enriched to allow screening for multiple cancers simultaneously. However, this assay has a low sensitivity, in particular in early lung cancer and breast cancer stages (Liu et al., 2020). As alternative, PCR based assays are described. However, these assays only detect the methylation levels of a very reduced number of markers (less than 10), e.g., by quantitative methylation specific PCR (qMSP) (Chen et al., 2020, Clin Epigenetics ;12(1):39). 202224094 4 In view of the above, there is a clear need for improved means and methods for early cancer detection, in particular for lung and breast cancer. SUMMARY The present invention addresses these needs and provides in a first aspect a combination of polynucleotides for the enrichment and/or detection of a panel of at least 4500 methylation sites in a sample comprising human DNA for cancer screening, wherein the methylation sites show a non-normal methylation pattern in at least one cancer training sample. This combination of polynucleotides detects and/or enriches a panel of at least 4500 methylation sites in a sample comprising human DNA, which has been identified after intensive comparison and analysis efforts, in particular a complex statistical and bioinformatic assessment and which represents the optimized output of clinically relevant methylation sites, selected from a number of more than 28 million CpG loci or sites available in the human genome. In particular, the panel as mentioned above was selected from over 450,000 methylation sites covered on the Illumina Infinium HumanMethylation450 BeadChip. To obtain the currently claimed optimized panel a discovery dataset comprising 95 and 68 matched tumor-normal samples for breast and non-small-cell lung cancer, respectively, was used. Relevant methylation sites were selected based on a combined application of paired t-tests and fold change calculations to methylation levels quantified as m-values which are approximately homoscedastic and, therefore, statistically more valid for the differential analysis of methylation levels. The accordingly selected sites were additionally enriched with sites localized within or nearby mRNA and 202224094 5 lncRNA genes that have been reported in the literature to provide a diagnostic, prognostic and/or predictive conclusion with respect to the presence of a cancer disease, in particular a breast or lung cancer. Specifically, to identify CpG sites with discriminative methylation levels in tumor- and normal cohorts firstly a statistical hypothesis testing, based on paired t-tests followed by a correction for false discovery rate, was performed which allowed to identify CpG sites with significantly different mean methylation levels in the tested groups. Subsequently, for all CpG sites, computation of the fold change (FC) of mean methylation levels in the two groups was performed. Finally, CpG sites with high significance, i.e., a small p-value obtained in the first step as described above, which also show a large FC in their mean methylation levels obtained in the second step as defined above, were selected. For this purpose, appropriate thresholds for p-values and the FC were applied. This innovative and unique approach yielded the currently claimed combination of polynucleotides. The combination of polynucleotides according to the present invention provides several advantages in comparison to screening approaches of the prior art. Firstly, it is capable of binding to a medium number of markers, i.e., methylation sites, which can be employed for enrichment of sample sequences and thereby reduces sequencing and analysis costs and at the same time allows for an increase of the sequencing depth. Secondly, in comparison to other small size solutions which only analyze up to 10 markers by qPCR, the combination of polynucleotides of the present invention drastically increases the number of features and thus improves the discriminative power of a classifier. The significantly increased number of markers, including correlated markers, 202224094 6 further allows for an improved statistic or bioinformation assessment and thus reduces prediction uncertainty. In a preferred embodiment of said combination of polynucleotides, said methylation sites are represented by nucleotide sequences in the human DNA and said polynucleotides are primers and/or probes designed to hybridize to said nucleotide sequences in the human DNA allowing for the enrichment and/or detection said methylation sites. It is further preferred that said non-normal methylation pattern is a differential methylation pattern, wherein methylated and/or unmethylated sites are present in a cancer training sample in comparison to a healthy sample. In another preferred embodiment the healthy sample is a tissue sample, preferably an FFPE tissue sample, spatially adjacent to the cancer training sample. In yet a further preferred embodiment said differential methylation pattern is present at a CpG site. According to another preferred embodiment of the present invention each polynucleotide has a length of about 50 to 150 nucleotides, preferably of about 120 nucleotides. It is further preferred that the sample comprising human DNA is a liquid biopsy sample or a tissue biopsy sample. It is particularly preferred that the human DNA is a cfDNA molecule or a genomic DNA molecule. In a further preferred embodiment, the methylation sites are located in or cover a multitude of genomic regions, 202224094 7 preferably genomic regions wherein a non-normal methylation pattern in at least one cancer training sample is present. It is further preferred that the methylation sites show a non-normal methylation pattern in at least one breast or lung cancer training sample. It is further preferred that the one or more primers and/or probes are designed to cover one or more methylation sites. According to another preferred embodiment the polynucleotides are designed to enrich and/or detect at least 4500 differentially methylated positions (DMPs) selected from Table 1. In a further aspect the present invention relates to a method of enriching DNA molecules derived from a subject’s sample, preferably a liquid biopsy or tissue biopsy sample, comprising: (a) modifying the DNA molecules to allow for determination of the methylation status of methylation sites, preferably by bisulfite-conversion or enzymatic conversion; (b) contacting the converted molecules with a combination of polynucleotides selected from the combination of polynucleotides as defined herein and enriching bisulfite- converted or enzymatically converted DNA molecules by hybridization capture. In a preferred embodiment the enrichment method additionally comprises the step (c) of determining the sequence of the enriched molecule, thereby also determining the methylation status of the enriched molecule. In yet another aspect the present invention relates to a method of diagnosing, prognosing or predicting a cancer 202224094 8 disease in a subject, comprising: (a) enriching DNA molecules derived from the subject’s sample; and determining the sequence and methylation status of the enriched DNA molecules, preferably according to the method as defined herein; (b) assessing the obtained sequence information, preferably on the basis of a database comprising information on cancer related methylation states, more preferably via a bioinformatic analysis; and (c) deriving a diagnostic, prognostic and/or predictive conclusion with respect to the presence of a cancer disease in the subject. In a preferred embodiment the method additionally comprises the step of evaluation of: (i) the subject’s imaging-based data, preferably derived from a mammography analysis, an ultra-low-dose (ULD) CT screening, medical images and/or pathology images; and/or (ii) the subject’s non-imaging based data, such as data on age, sex, race, characteristics of cancer phenotype, histologic characteristics, stage of development of cancer, histologic subtype, detectable molecular changes, preferably on the level of the genome, transcriptome, metabolome, proteome, glycome or lipidome, biomarkers and/or laboratory tests, wherein the results of the evaluation(s) contribute to the diagnostic, prognostic and/or predictive conclusion with respect to the presence of a cancer disease in the subject. BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 shows a schematic illustration depicting the steps which led to the identification of the panel for cancer screening according to the present invention. In an initial step (1) publicly available The Cancer Genome Atlas (TCGA) data were analyzed, followed by a statistical analysis (2). In parallel a literature analysis based on data from 202224094 9 different sample origins and detection methods (3) was performed. The combination of the analysis outcome resulted in the panel for cancer screening (4) according to the present invention. FIG. 2 shows a further schematic illustration of an embodiment of the invention, namely the steps of a diagnostic/prognostic method according to the invention. Based on the task to screen a subject for the presence of a cancer disease or the likelihood to develop a cancer disease (10), different steps can be performed. One important step is the performance of an analysis of a subject's sample obtained in a minimal invasive blood test comprising the determination of the methylation status of the methylation sites of the panel for cancer screening of the present invention (11) and thus provides a first diagnostic/prognostic conclusion on the presence of a cancer disease or the likelihood of developing a cancer disease. In a further, parallel step imaging-based screening data of the subject, which has been obtained, e.g., with ULD CT screening or mammography, is analyzed (12) contributing to the diagnostic/prognostic conclusion on the presence of a cancer disease or the likelihood of developing a cancer disease. In a third approach non-imaging-based data, e.g., obtained from protein screens or the like, is analyzed (13) further contributing to the diagnostic/prognostic conclusion on the presence of a cancer disease or the likelihood of developing a cancer disease. The combination of the results (14) allows for a summary conclusion on the presence of a cancer disease or the likelihood of developing a cancer disease. DETAILED DESCRIPTION OF EMBODIMENTS 202224094 10 Although the present invention will be described with respect to particular embodiments, this description is not to be construed in a limiting sense. Before describing in detail exemplary embodiments of the present invention, definitions important for understanding the present invention are given. As used in this specification and in the appended claims, the singular forms of "a" and "an" also include the respective plurals unless the context clearly dictates otherwise. In the context of the present invention, the terms "about" and "approximately" denote an interval of accuracy that a person skilled in the art will understand to still ensure the technical effect of the feature in question. The term typically indicates a deviation from the indicated numerical value of ±20 %, preferably ±15 %, more preferably ±10 %, and even more preferably ±5 %. It is to be understood that the term "comprising" is not limiting. For the purposes of the present invention the term "consisting of" or "essentially consisting of" is considered to be a preferred embodiment of the term "comprising of". If hereinafter a group is defined to comprise at least a certain number of embodiments, this is meant to also encompass a group which preferably consists of these embodiments only. Furthermore, the terms "(i)", "(ii)", "(iii)" or "(a)", "(b)", "(c)", "(d)", or "first", "second", "third" etc. and the like in the description or in the claims, are used for distinguishing between similar or structural elements and not necessarily for describing a sequential or chronological order. 202224094 11 It is to be understood that the terms so used are interchangeable under appropriate circumstances and that the embodiments of the invention described herein are capable of operation in other sequences than described or illustrated herein. In case the terms relate to steps of a method, procedure or use there is no time or time interval coherence between the steps, i.e., the steps may be carried out simultaneously or there may be time intervals of seconds, minutes, hours, days, weeks etc. between such steps, unless otherwise indicated. It is to be understood that this invention is not limited to the particular methodology, protocols etc. described herein as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to limit the scope of the present invention that will be limited only by the appended claims. The drawings are to be regarded as being schematic representations and elements illustrated in the drawings are not necessarily shown to scale. Rather, the various elements are represented such that their function and general purpose become apparent to a person skilled in the art. Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art. Independent of the grammatical term usage, individuals with male, female or other gender identities are included within the term. 202224094 12 As has been set out above, the present invention concerns in one aspect a combination of polynucleotides for the enrichment and/or detection of a panel of at least 4500 methylation sites in a sample comprising human DNA for cancer screening, wherein the methylation sites show a non-normal methylation pattern in at least one cancer training sample. The term "combination of polynucleotides" as used herein refers to groupings of polynucleotides which can be provided in different forms. In one embodiment, the combination of polynucleotides may be provided in the form of a liquid-phase reagent or a set of reagents. For example, the reagent or set of reagents may comprise the polynucleotides in dissolved or soluble state. In further embodiments the reagent, reagents or set of reagents may be provided as liquid or in a dried from, e.g. freeze-dried. The reagent or set of reagents may accordingly be provided or optimized for resuspension. The term "methylation sites" as used herein relates to the specific sites in a genomic sequence which are modified by the addition of a methyl group to a cytosine which is converted to a 5-methylcytosine, or, in certain situations, the removal of a methyl group from the 5-methylcytosine. The methylation of DNA is a form of epigenetic modification which has the capability of altering the expression of genes and other elements and may accordingly have an effect on, e.g., silencing of tumor suppressor genes and/or increasing the expression of oncogenes, etc., thus potentially contributing to the development of a cancer disease in a subject. Typically, the methylation site is a 5’-cytosine-phosphate- guanine-3’ (CpG) dinucleotide site. The methylation sites are typically distributed throughout the genome and not confined to expressed genes. In many cases, methylation sites are 202224094 13 located in promoter or regulatory regions. The analysis of the methylation status at certain methylation sites as defined herein is based on specific techniques for the detection of methyl groups. Typically, DNA molecules to be analyzed for the presence of their methylation status are specifically processed to preserve the methylation status information. Such processing may be based on techniques such as bisulfite conversion or enzymatic conversion. The "bisulfite conversion" comprises the treatment of DNA molecules with bisulfite which converts cytosine to uracil but does not convert 5-methylcytosines. Subsequent amplification, which turns uracil to thymine, is usually carried out using PCR or methylation-specific PCR (MSP). In PCR amplification uracil is recognized as thymine and the opposite strand is filled in with adenine due to complementary base pairing, while cytosines are paired with guanines in bisulfite-untreated stretches. This results in two DNA sequences (converted Cs for unmethylated and unconverted Cs for methylated), of which the converted one has C->U transitions at the unmethylated sites and is then paired with A instead of G in DNA sequencing. In the alternative method of "enzymatic conversion" instead of a chemical conversion of unmethylated cytosines an enzymatic conversion is performed. Typically, a set of two enzymes is used. For example, the enzymes TET2 and T4-BGT are used to convert 5-methylcytosines into products that cannot be deaminated by the enzyme APOBEC. In a second reaction, the enzyme APOBEC deaminates unmodified cytosines by converting them to uracils. Further analysis steps correspond to the bisulfite approach described above. The term "non-normal methylation pattern" as used in the context of the present invention relates to the methylation of a multitude of methylation sites as defined herein, 202224094 14 wherein said methylation does not occur in "normal" tissues or samples, e.g., tissues or samples derived from healthy subjects, preferably subjects not afflicted by a cancer disease, more preferably subjects not afflicted by a lung cancer or subjects not afflicted by a breast cancer. Instead said methylation occurs in at least one cancer training sample. In certain embodiments, a non-normal methylation pattern may also be given in case said methylation occurs in "normal" tissues or samples, e.g., tissues or samples derived from healthy subjects, preferably subjects not afflicted by a cancer disease, more preferably subjects not afflicted by a lung cancer or subjects not afflicted by a breast cancer, whereas said methylation does not occur in at least one cancer training sample. These normal tissues, which are understood in the context of the present invention as "healthy" samples may preferably be derived from a tissue sample which was obtained from a normal zone spatially adjacent to a cancer training sample. For example, cancer samples may be or may have been obtained or removed from the body by means of a biopsy. The accordingly obtained direct tumor tissue is accompanied and, during the analysis, is also compared with spatially adjacent "normal tissue" or "healthy tissue", i.e., from a normal zone. Both tissues, healthy and cancerous, are preferably FFPE (formalin-fixed paraffin- embedded) tissues obtained by biopsy. The term "cancer" or "cancer disease" as used herein refers to any cancer, tumor or under-controlled or uncontrolled cellular proliferation. Examples of cancer diseases or corresponding medical conditions include a stomach, colon, rectal, liver, pancreatic, lung, breast, cervix uteri, corpus uteri, ovary, prostate, testis, bladder, renal, brain/CNS, head and neck, or throat cancer, Hodgkin's disease, non- Hodgkin's lymphoma, multiple myeloma, leukemia, melanoma skin 202224094 15 cancer, non-melanoma skin cancer, acute lymphocytic leukemia, acute myelogenous leukemia, Ewing's sarcoma, small cell lung cancer, choriocarcinoma, rhabdomyosarcoma, Wilms' tumor, neuroblastoma, hairy cell leukemia, mouth/pharynx, esophagus, larynx, kidney cancer, lymphoma, or any subtype thereof. It is preferred that the cancer disease is a lung cancer or a breast cancer. Further, the cancer disease may further include the presence of pre-invasive lesions or a pre- cancerous cell population, or a predisposition for cancer or tumor which is reflected by the presence of certain DNA methylation patterns as enshrined in the DMPs of the panel of the present invention. The term "cancer training sample" relates to a sample for which independent information on the affliction by a cancer disease has been obtained, i.e., the cancerous status has been confirmed, e.g., by histological or molecule analysis. It is preferred that the cancer training sample is a lung cancer sample (lung cancer training sample) or a breast cancer sample (breast cancer training sample). The present invention further envisages the analysis or derivation of information not only from one cancer training sample, but form a larger number of training samples, e.g., 5, 10, 15, 20, 25, 50, 100, 500, 1000 or more or any number in between the mentioned numbers. The group of cancer training samples may, in certain embodiments may be derived from identical cancer types, e.g., lung or breast cancer. In specific embodiments, the present invention also envisages a mixture of cancer types, e.g., a mixture of lung and breast cancer types. Information on the methylation status of the cancer training samples may, in certain embodiments, be derivable from data repositories or databases, or may, in certain embodiments, be provided de novo. 202224094 16 A non-normal methylation pattern within the context of the present invention may thus be based on the presence of a differentially methylated position (DMP), which shows a methylation status variation in a normal tissue vs. a tissue derived from a subject afflicted by a cancer disease, e.g., a subject afflicted by a lung cancer or a subject afflicted by a breast cancer. Accordingly, in preferred embodiments, the non-normal methylation pattern is a differential methylation pattern, wherein typically methylated sites are present in a cancer training sample in comparison to a healthy sample. It is also possible, that at certain specific genomic positions, the reverse methylation status exists, wherein unmethylated sites are present in a cancer training sample in comparison to a healthy sample. The differential methylation pattern underlying the present invention and enshrined in the DMPs of Table 1 is hence not restricted to a methylated cancerous vs. unmethylated non-cancerous pattern, but merely reflects any registered different methylation situation (methylated or unmethylated) in a comparison of the cancer training sample vs. the healthy sample. The panel of at least 4500 methylation sites in a sample comprising human DNA according to the present invention is capable of distinguishing a cancerous target subject's sample from a non-cancerous. For example, the panel may comprise at least 4500, or at least 4550 or all 4556 different DMPs, or any number of DMPs in between the mentioned numbers, e.g., of the DMPs of Table 1. According to specific embodiments, the methylation sites reflected by the panel as described herein or DMPs covered by the panel are located in more than one genomic location, preferably in a multitude of genomic locations. For example, the methylation sites may be located on different 202224094 17 chromosomes, different chromosomal arms, etc. The DMPs of Table 1 or a subset thereof may accordingly cover regions on all human chromosomes, or 90%, 80%, 70%, 60%, 50%, 40% or 30% of the human chromosomes. A selection of chromosome-based DMPs according to project needs and diagnostic purposes is further envisaged by the present invention. A selection and grouping of such DMPs, e.g., of the DMPs of Table 1, is easily implementable with the Illumina ID system and, for example, its connection to genomic browsers or other suitable bioinformatic tools. In certain embodiments, the differential methylation status may be determined on a larger scale, e.g., on the basis of regional or chromosomal methylation states. It is envisaged that the genomic regions selected are those in which a non-normal methylation pattern in at least one cancer training sample is present. The present invention further envisages the use of the concept of differentially methylated regions (DMRs), which reflect a summary or average regional methylation status in a larger section of a genome, e.g., 1 kb, 2 kb, 3 kb, 10 kb, 20 kb, 50 kb, 100 kb, 500 kb or more or any value in between the mentioned values. For example, the status may be "methylated" if 50% or more of the CpG sites or DMPs (e.g., the DMPs as mentioned in Table 1 or a subset thereof) in the region are methylated and "unmethylated" if less than 50% of the CpG sites in the region are methylated. In further embodiments the regional DNA methylation status may be a composite methylation status, with the average methylation status as defined above as one possible characteristic. Further elements of the composite methylation status may include the methylation status of known genomic elements, e.g., CpG islands, genes, gene promoters, enhancers, transcription factor binding sites, including extensions to said sections, e.g., within 1 kb around transcription start site etc. In 202224094 18 further specific embodiments the regional DNA methylation status may accordingly be defined with respect to known genomic elements, e.g., CpG islands, genes, gene promoters, enhancers, transcription factor binding sites, including extensions to said sections, e.g., within 1 kb around transcription start site etc. In further specific embodiments the regional DNA methylation status may correspond to the mean methylation levels of all CpG sites in a region. Information on DMRs may accordingly be for additional diagnostic, prognostic or predictive assessment activities. In particularly preferred embodiments, the DMPs at least comprised in the methylation site panel are the DMPs listed in Table 1 or a sub-section thereof. Preferably, the panel comprises a medium number of DMPs, e.g., at least 4500 or all 4556 DMPs of the DMPs mentioned in Table 1. In a specific embodiment, the panel comprises at least all DMPs mentioned in Table 1. In certain embodiments, the panel may, in addition to the DMPs of Table 1, comprise further DMPs, e.g., obtained from further studies or future analysis. In another set of embodiments, the panel may comprise a subset of the DMPs of Table 1, e.g. a feature which allows for an adaptation of the selection of the DMPs to a target subject or patient, or a subset as reflected by the above indicated numbers of DMPs. For example, the subset of DMPs of Table 1 may be associated with lung cancer, or the subset DMPs of Table 1 may be associated with breast cancer. The definition or selection of a corresponding sub-set of DMPs of Table 1 may be based on additional scientific evidence, e.g., as published or derivable from suitable databases as described herein. 202224094 19 Table 1 DMPs according to the invention. No.  DMP ID  No.  DMP ID  No.  DMP ID  No.  DMP ID  No.  DMP ID  No.  DMP ID  1  cg00001747  761  cg08884571  1521  cg17863743  2281  cg27122213  3041  cg25982483  3801  cg21816532  2  cg00002719  762  cg08892613  1522  cg17911318  2282  cg27130240  3042  cg26019112  3802  cg22583148  3  cg00003298  763  cg08893692  1523  cg17919004  2283  cg27170427  3043  cg26024530  3803  cg23217463  4  cg00012529  764  cg08901662  1524  cg17922359  2284  cg27179533  3044  cg26059468  3804  cg24889708  5  cg00017437  765  cg08934846  1525  cg17939040  2285  cg27189087  3045  cg26074603  3805  cg26279336  6  cg00063471  766  cg08949339  1526  cg17941572  2286  cg27200446  3046  cg26102295  3806  cg03371669  7  cg00065215  767  cg08958294  1527  cg17983217  2287  cg27204616  3047  cg26104752  3807  cg03874199  8  cg00076538  768  cg09000583  1528  cg17983265  2288  cg27218892  3048  cg26130488  3808  cg06473181  9  cg00089798  769  cg09007841  1529  cg17985646  2289  cg27232866  3049  cg26149244  3809  cg06571387  10  cg00097146  770  cg09010671  1530  cg18035399  2290  cg27243490  3050  cg26156256  3810  cg11754318  11  cg00100121  771  cg09013220  1531  cg18040901  2291  cg27252696  3051  cg26199241  3811  cg12268637  12  cg00106345  772  cg09016242  1532  cg18045100  2292  cg27260772  3052  cg26225694  3812  cg12503267  13  cg00124375  773  cg09053680  1533  cg18055007  2293  cg27267227  3053  cg26246807  3813  cg15767955  14  cg00129232  774  cg09068128  1534  cg18063733  2294  cg27277463  3054  cg26247186  3814  cg17512364  15  cg00164949  775  cg09094964  1535  cg18070676  2295  cg27282900  3055  cg26252167  3815  cg18022224  16  cg00177787  776  cg09106903  1536  cg18077971  2296  cg27290624  3056  cg26281789  3816  cg20292112  17  cg00203347  777  cg09124223  1537  cg18081940  2297  cg27301256  3057  cg26327071  3817  cg23130254  18  cg00217080  778  cg09130077  1538  cg18082337  2298  cg27317046  3058  cg26365545  3818  cg04676799  19  cg00249511  779  cg09142313  1539  cg18087672  2299  cg27326452  3059  cg26379859  3819  cg06682875  20  cg00251610  780  cg09149672  1540  cg18092028  2300  cg27360326  3060  cg26386409  3820  cg07405021  21  cg00254133  781  cg09159452  1541  cg18096251  2301  cg27363327  3061  cg26394244  3821  cg07600499  22  cg00259234  782  cg09165441  1542  cg18099070  2302  cg27364741  3062  cg26396278  3822  cg07644368  23  cg00267596  783  cg09170112  1543  cg18103859  2303  cg27393010  3063  cg26398467  3823  cg07712493  24  cg00295794  784  cg09193347  1544  cg18115040  2304  cg27398263  3064  cg26422458  3824  cg12880658  25  cg00299737  785  cg09226786  1545  cg18116285  2305  cg27406975  3065  cg26460471  3825  cg16265906  26  cg00334063  786  cg09234518  1546  cg18121003  2306  cg27422872  3066  cg26517663  3826  cg18520851  27  cg00347563  787  cg09234616  1547  cg18121066  2307  cg27494647  3067  cg26567423  3827  cg02539083  28  cg00370229  788  cg09236176  1548  cg18122501  2308  cg27501878  3068  cg26595643  3828  cg07550362  29  cg00376544  789  cg09238180  1549  cg18130044  2309  cg27504292  3069  cg26597242  3829  cg08202265  30  cg00379720  790  cg09251197  1550  cg18155853  2310  cg27504802  3070  cg26601431  3830  cg09236284  31  cg00396667  791  cg09258813  1551  cg18156204  2311  cg27528510  3071  cg26654934  3831  cg09910635  32  cg00400827  792  cg09291131  1552  cg18172877  2312  cg27549720  3072  cg26674943  3832  cg10997627  33  cg00436476  793  cg09321400  1553  cg18177414  2313  cg27555582  3073  cg26727488  3833  cg14221171  34  cg00440032  794  cg09323727  1554  cg18197392  2314  cg27606499  3074  cg26738880  3834  cg15954041  35  cg00459623  795  cg09360770  1555  cg18206027  2315  cg27615388  3075  cg26836696  3835  cg19212224  36  cg00474840  796  cg09364122  1556  cg18229521  2316  cg27616039  3076  cg26842720  3836  cg19219624  37  cg00495860  797  cg09385093  1557  cg18231054  2317  cg27644733  3077  cg26947626  3837  cg00149734  38  cg00503383  798  cg09422450  1558  cg18235050  2318  cg27649037  3078  cg26970841  3838  cg00198994  39  cg00514609  799  cg09424526  1559  cg18235734  2319  cg27649239  3079  cg26995255  3839  cg00618725  202224094 20 No.  DMP ID  No.  DMP ID  No.  DMP ID  No.  DMP ID  No.  DMP ID  No.  DMP ID  40  cg00515457  800  cg09432775  1560  cg18249173  2320  cg27655158  3080  cg27058257  3840  cg00639517  41  cg00552087  801  cg09434193  1561  cg18249580  2321  cg27663938  3081  cg27131891  3841  cg00904483  42  cg00557947  802  cg09442654  1562  cg18249634  2322  cg00001583  3082  cg27170782  3842  cg00981003  43  cg00582524  803  cg09465698  1563  cg18250028  2323  cg00028935  3083  cg27177554  3843  cg01204683  44  cg00582971  804  cg09473364  1564  cg18267049  2324  cg00063174  3084  cg27357571  3844  cg01341123  45  cg00585901  805  cg09474331  1565  cg18276638  2325  cg00084798  3085  cg27362525  3845  cg02022136  46  cg00619126  806  cg09489306  1566  cg18279094  2326  cg00133595  3086  cg27376182  3846  cg02172216  47  cg00642460  807  cg09490603  1567  cg18282849  2327  cg00153110  3087  cg27421939  3847  cg02330106  48  cg00647046  808  cg09513990  1568  cg18318649  2328  cg00158528  3088  cg27434509  3848  cg02381948  49  cg00647217  809  cg09515953  1569  cg18322569  2329  cg00175709  3089  cg27477504  3849  cg02634492  50  cg00663077  810  cg09537620  1570  cg18325622  2330  cg00212119  3090  cg27510182  3850  cg02750154  51  cg00680551  811  cg09542210  1571  cg18343437  2331  cg00347938  3091  cg27513573  3851  cg02792401  52  cg00683332  812  cg09549813  1572  cg18350739  2332  cg00377087  3092  cg27527345  3852  cg02802904  53  cg00685614  813  cg09557387  1573  cg18358894  2333  cg00379648  3093  cg27563985  3853  cg02941816  54  cg00688447  814  cg09559163  1574  cg18362003  2334  cg00384539  3094  cg27587310  3854  cg03271907  55  cg00731785  815  cg09568464  1575  cg18372607  2335  cg00415665  3095  cg27616751  3855  cg03292473  56  cg00735923  816  cg09570682  1576  cg18384778  2336  cg00466108  3096  cg27636310  3856  cg03344290  57  cg00765705  817  cg09578028  1577  cg18397073  2337  cg00478361  3097  cg00743929  3857  cg03639152  58  cg00773902  818  cg09578475  1578  cg18401367  2338  cg00480389  3098  cg00777121  3858  cg03748042  59  cg00777546  819  cg09591072  1579  cg18417954  2339  cg00516513  3099  cg00980904  3859  cg04271445  60  cg00778995  820  cg09591867  1580  cg18423210  2340  cg00530925  3100  cg01568433  3860  cg04425788  61  cg00790098  821  cg09607276  1581  cg18424634  2341  cg00602245  3101  cg02817007  3861  cg04436810  62  cg00793935  822  cg09624466  1582  cg18438793  2342  cg00674365  3102  cg02930432  3862  cg04473030  63  cg00800229  823  cg09626894  1583  cg18443359  2343  cg00711088  3103  cg03297783  3863  cg04540870  64  cg00807871  824  cg09671258  1584  cg18447772  2344  cg00853103  3104  cg04540383  3864  cg04854917  65  cg00812438  825  cg09682330  1585  cg18448581  2345  cg00868383  3105  cg05546296  3865  cg04876500  66  cg00812833  826  cg09695735  1586  cg18448949  2346  cg00983904  3106  cg05885095  3866  cg05596517  67  cg00817367  827  cg09705457  1587  cg18456523  2347  cg00995807  3107  cg06063729  3867  cg05611777  68  cg00830435  828  cg09734394  1588  cg18479593  2348  cg01024175  3108  cg06117233  3868  cg05714579  69  cg00840332  829  cg09734791  1589  cg18496841  2349  cg01031101  3109  cg06172942  3869  cg05972792  70  cg00844246  830  cg09765089  1590  cg18502142  2350  cg01047586  3110  cg06174454  3870  cg06070493  71  cg00875805  831  cg09774787  1591  cg18507379  2351  cg01085837  3111  cg06375085  3871  cg06095790  72  cg00907288  832  cg09777525  1592  cg18563413  2352  cg01135464  3112  cg06821120  3872  cg06209143  73  cg00910015  833  cg09792881  1593  cg18564898  2353  cg01176141  3113  cg06980053  3873  cg06216683  74  cg00910518  834  cg09795588  1594  cg18579862  2354  cg01193690  3114  cg07130266  3874  cg06401999  75  cg00914041  835  cg09797577  1595  cg18582992  2355  cg01239704  3115  cg07344955  3875  cg06566239  76  cg00925616  836  cg09844474  1596  cg18617005  2356  cg01287975  3116  cg08047457  3876  cg06709661  77  cg00939495  837  cg09850478  1597  cg18623980  2357  cg01313313  3117  cg08078366  3877  cg06874216  78  cg00960305  838  cg09854626  1598  cg18627235  2358  cg01330456  3118  cg09386807  3878  cg07126542  79  cg00963378  839  cg09858188  1599  cg18627442  2359  cg01397679  3119  cg10152523  3879  cg07367735  80  cg00970396  840  cg09863247  1600  cg18637486  2360  cg01442005  3120  cg11035216  3880  cg07448909  81  cg00984146  841  cg09881253  1601  cg18652900  2361  cg01447112  3121  cg12966367  3881  cg07453748  82  cg00986824  842  cg09887059  1602  cg18669209  2362  cg01577083  3122  cg13257331  3882  cg07554771  83  cg00991875  843  cg09967192  1603  cg18675097  2363  cg01594538  3123  cg13497155  3883  cg07638938  202224094 21 No.  DMP ID  No.  DMP ID  No.  DMP ID  No.  DMP ID  No.  DMP ID  No.  DMP ID  84  cg01009664  844  cg09969277  1604  cg18694169  2364  cg01712692  3124  cg13872831  3884  cg07828472  85  cg01016662  845  cg09971314  1605  cg18698788  2365  cg01720475  3125  cg14884256  3885  cg07933035  86  cg01040523  846  cg09979641  1606  cg18705773  2366  cg01729827  3126  cg15043975  3886  cg08883995  87  cg01055386  847  cg10007534  1607  cg18716164  2367  cg01765882  3127  cg1542687  3887  cg09154334  88  cg01065161  848  cg10034364  1608  cg18721420  2368  cg01890568  3128  cg19152024  3888  cg09450835  89  cg01088410  849  cg10034890  1609  cg18722847  2369  cg02017450  3129  cg19811994  3889  cg09757049  90  cg01089498  850  cg10043865  1610  cg18724565  2370  cg02036261  3130  cg20119308  3890  cg09858782  91  cg01128460  851  cg10056132  1611  cg18725867  2371  cg02044349  3131  cg20826201  3891  cg09993459  92  cg01140660  852  cg10065209  1612  cg18740893  2372  cg02064848  3132  cg21372200  3892  cg10036895  93  cg01146232  853  cg10088985  1613  cg18746831  2373  cg02159731  3133  cg21418575  3893  cg10215460  94  cg01163842  854  cg10094616  1614  cg18770350  2374  cg02167020  3134  cg21522636  3894  cg10333959  95  cg01182863  855  cg10106804  1615  cg18782604  2375  cg02172150  3135  cg21554552  3895  cg10366851  96  cg01218619  856  cg10109500  1616  cg18786593  2376  cg02181080  3136  cg21908110  3896  cg10502904  97  cg01221209  857  cg10120897  1617  cg18786873  2377  cg02213103  3137  cg22090713  3897  cg10744297  98  cg01226963  858  cg10122865  1618  cg18789918  2378  cg02223801  3138  cg22796393  3898  cg11019008  99  cg01235820  859  cg10136354  1619  cg18794404  2379  cg02245566  3139  cg23147362  3899  cg11216456  100  cg01268824  860  cg10152131  1620  cg18840956  2380  cg02245794  3140  cg24298409  3900  cg11223735  101  cg01272937  861  cg10155432  1621  cg18847089  2381  cg02286091  3141  cg24859722  3901  cg11235543  102  cg01283246  862  cg10168086  1622  cg18862481  2382  cg02288825  3142  cg25486143  3902  cg11302655  103  cg01324372  863  cg10168149  1623  cg18866599  2383  cg02305377  3143  cg25747192  3903  cg11309842  104  cg01381846  864  cg10182317  1624  cg18873878  2384  cg02328660  3144  cg26093954  3904  cg11948988  105  cg01388649  865  cg10184889  1625  cg18892424  2385  cg02387803  3145  cg26357744  3905  cg12040555  106  cg01405040  866  cg10184983  1626  cg18914211  2386  cg02400740  3146  cg27149285  3906  cg12434587  107  cg01419831  867  cg10188823  1627  cg18920423  2387  cg02403239  3147  cg27569446  3907  cg12575438  108  cg01439876  868  cg10192893  1628  cg18924324  2388  cg02423318  3148  cg01879757  3908  cg12981137  109  cg01445580  869  cg10222027  1629  cg18932798  2389  cg02447304  3149  cg02286533  3909  cg13171643  110  cg01452847  870  cg10224098  1630  cg18947951  2390  cg02470440  3150  cg04110421  3910  cg13405636  111  cg01464835  871  cg10243459  1631  cg18952796  2391  cg02493602  3151  cg04582861  3911  cg13474692  112  cg01496199  872  cg10249375  1632  cg18961681  2392  cg02523844  3152  cg04658354  3912  cg14194875  113  cg01518607  873  cg10253847  1633  cg18991611  2393  cg02531439  3153  cg05815247  3913  cg14263093  114  cg01518889  874  cg10256242  1634  cg19006220  2394  cg02542748  3154  cg06001716  3914  cg14273607  115  cg01521036  875  cg10263682  1635  cg19021412  2395  cg02631468  3155  cg06973652  3915  cg14312783  116  cg01528052  876  cg10292154  1636  cg19053239  2396  cg02637474  3156  cg08386886  3916  cg14418963  117  cg01532168  877  cg10293403  1637  cg19054524  2397  cg02656891  3157  cg08993267  3917  cg14434995  118  cg01536987  878  cg10303487  1638  cg19057986  2398  cg02667414  3158  cg09441966  3918  cg14475381  119  cg01544903  879  cg10356613  1639  cg19068510  2399  cg02671880  3159  cg09831010  3919  cg14485787  120  cg01565320  880  cg10364040  1640  cg19082708  2400  cg02695116  3160  cg10609677  3920  cg14677612  121  cg01576677  881  cg10375078  1641  cg19099050  2401  cg02723533  3161  cg10893007  3921  cg15312358  122  cg01586506  882  cg10375890  1642  cg19127283  2402  cg02730714  3162  cg11126247  3922  cg15367698  123  cg01642521  883  cg10387551  1643  cg19129687  2403  cg02780849  3163  cg11529738  3923  cg15658262  124  cg01667007  884  cg10397440  1644  cg19142026  2404  cg02792792  3164  cg11964474  3924  cg15986238  125  cg01670677  885  cg10418524  1645  cg19149132  2405  cg02853616  3165  cg12182452  3925  cg16159175  126  cg01688536  886  cg10435816  1646  cg19166302  2406  cg02864844  3166  cg12984107  3926  cg16259047  127  cg01703246  887  cg10439765  1647  cg19186145  2407  cg02892286  3167  cg13782816  3927  cg16648911  202224094 22 No.  DMP ID  No.  DMP ID  No.  DMP ID  No.  DMP ID  No.  DMP ID  No.  DMP ID  128  cg01715455  888  cg10440578  1648  cg19209066  2408  cg02914422  3168  cg14687474  3928  cg16698623  129  cg01718447  889  cg10443049  1649  cg19212767  2409  cg02970836  3169  cg14947218  3929  cg16942891  130  cg01735384  890  cg10502231  1650  cg19212949  2410  cg03007522  3170  cg15419295  3930  cg17380475  131  cg01739725  891  cg10507988  1651  cg19223299  2411  cg03036592  3171  cg16006004  3931  cg17686260  132  cg01749491  892  cg10512745  1652  cg19254119  2412  cg03043665  3172  cg16029534  3932  cg18038372  133  cg01753252  893  cg10530883  1653  cg19256731  2413  cg03045635  3173  cg16630982  3933  cg18064754  134  cg01759597  894  cg10575986  1654  cg19288904  2414  cg03065447  3174  cg16919093  3934  cg18128898  135  cg01760475  895  cg10615414  1655  cg19295951  2415  cg03072195  3175  cg16963062  3935  cg18148349  136  cg01764252  896  cg10617909  1656  cg19304150  2416  cg03109827  3176  cg17301289  3936  cg18247239  137  cg01765111  897  cg10643691  1657  cg19324997  2417  cg03111498  3177  cg18372208  3937  cg18460575  138  cg01774894  898  cg10659805  1658  cg19355186  2418  cg03114255  3178  cg18830083  3938  cg18502933  139  cg01779765  899  cg10703826  1659  cg19403104  2419  cg03129103  3179  cg19088651  3939  cg18581292  140  cg01781974  900  cg10707788  1660  cg19442495  2420  cg03146993  3180  cg19442659  3940  cg18594706  141  cg01783070  901  cg10723962  1661  cg19456540  2421  cg03149560  3181  cg19454999  3941  cg18632220  142  cg01816146  902  cg10741153  1662  cg19464917  2422  cg03225817  3182  cg19531713  3942  cg18642179  143  cg01819142  903  cg10746936  1663  cg19483465  2423  cg03234732  3183  cg20187250  3943  cg18651291  144  cg01824948  904  cg10755235  1664  cg19484420  2424  cg03276000  3184  cg20760063  3944  cg18778347  145  cg01832036  905  cg10767312  1665  cg19486070  2425  cg03287111  3185  cg21253966  3945  cg18862686  146  cg01834022  906  cg10784273  1666  cg19488620  2426  cg03290602  3186  cg24806953  3946  cg19054785  147  cg01851378  907  cg10787000  1667  cg19497031  2427  cg03323462  3187  cg24900425  3947  cg19126889  148  cg01851968  908  cg10788735  1668  cg19504702  2428  cg03356595  3188  cg25067162  3948  cg19179102  149  cg01881590  909  cg10799055  1669  cg19507206  2429  cg03396103  3189  cg25288140  3949  cg19680672  150  cg01893212  910  cg10835584  1670  cg19513834  2430  cg03409187  3190  cg25738236  3950  cg19806483  151  cg01897797  911  cg10853830  1671  cg19533977  2431  cg03442569  3191  cg26276233  3951  cg20537325  152  cg01921432  912  cg10860802  1672  cg19552441  2432  cg03520644  3192  cg26370022  3952  cg20778669  153  cg01925891  913  cg10861897  1673  cg19578835  2433  cg03544320  3193  cg26891576  3953  cg22575127  154  cg01939477  914  cg10896862  1674  cg19587904  2434  cg03632623  3194  cg27581762  3954  cg22785261  155  cg01959730  915  cg10903903  1675  cg19592336  2435  cg03686593  3195  cg01251360  3955  cg22939703  156  cg01972576  916  cg10932018  1676  cg19595750  2436  cg03730428  3196  cg01857829  3956  cg23004031  157  cg01972751  917  cg10940462  1677  cg19602728  2437  cg03735888  3197  cg04398983  3957  cg23235067  158  cg01995743  918  cg10956848  1678  cg19619405  2438  cg03752218  3198  cg05785947  3958  cg23239690  159  cg02000882  919  cg10974980  1679  cg19624849  2439  cg03826594  3199  cg06875305  3959  cg23465978  160  cg02013838  920  cg10979436  1680  cg19631815  2440  cg03854913  3200  cg07762788  3960  cg23998405  161  cg02018277  921  cg10980436  1681  cg19653212  2441  cg03907855  3201  cg08616585  3961  cg24580056  162  cg02027945  922  cg10982364  1682  cg19656282  2442  cg03951603  3202  cg09220040  3962  cg24747557  163  cg02041108  923  cg11003573  1683  cg19675288  2443  cg03952361  3203  cg09406989  3963  cg24755725  164  cg02058408  924  cg11005831  1684  cg19712603  2444  cg03978375  3204  cg11255163  3964  cg24810646  165  cg02067712  925  cg11017065  1685  cg19729116  2445  cg03983645  3205  cg11667754  3965  cg25063211  166  cg02075410  926  cg11022432  1686  cg19738283  2446  cg04048259  3206  cg16739895  3966  cg25145165  167  cg02081266  927  cg11030264  1687  cg19740859  2447  cg04063945  3207  cg17655614  3967  cg25394042  168  cg02093112  928  cg11036833  1688  cg19752861  2448  cg04095724  3208  cg20716119  3968  cg25557018  169  cg02093732  929  cg11071231  1689  cg19757573  2449  cg04145287  3209  cg22832044  3969  cg25946389  170  cg02096296  930  cg11081307  1690  cg19760241  2450  cg04181013  3210  cg23989635  3970  cg25974017  171  cg02101773  931  cg11130317  1691  cg19772399  2451  cg04218812  3211  cg24765079  3971  cg26102564  202224094 23 No.  DMP ID  No.  DMP ID  No.  DMP ID  No.  DMP ID  No.  DMP ID  No.  DMP ID  172  cg02109189  932  cg11144753  1692  cg19777067  2452  cg04290346  3212  cg26508465  3972  cg26127080  173  cg02119792  933  cg11146691  1693  cg19792599  2453  cg04301104  3213  cg00905524  3973  cg26188698  174  cg02143877  934  cg11157172  1694  cg19806642  2454  cg04330449  3214  cg01024168  3974  cg26201213  175  cg02155398  935  cg11171221  1695  cg19807257  2455  cg04352272  3215  cg01215762  3975  cg26279216  176  cg02156680  936  cg11172693  1696  cg19808978  2456  cg04363624  3216  cg01354473  3976  cg26529877  177  cg02164046  937  cg11174855  1697  cg19809791  2457  cg04413320  3217  cg01397139  3977  cg26950715  178  cg02164574  938  cg11183365  1698  cg19814400  2458  cg04467162  3218  cg01819512  3978  cg26976729  179  cg02215070  939  cg11193865  1699  cg19852958  2459  cg04487296  3219  cg01891966  3979  cg27000233  180  cg02222235  940  cg11198128  1700  cg19859290  2460  cg04507915  3220  cg02483701  3980  cg27041381  181  cg02232704  941  cg11201447  1701  cg19861741  2461  cg04562217  3221  cg02643054  3981  cg27056559  182  cg02237540  942  cg11213520  1702  cg19871940  2462  cg04574507  3222  cg02886033  3982  cg27429313  183  cg02253760  943  cg11213574  1703  cg19893751  2463  cg04591032  3223  cg03217995  3983  cg27483317  184  cg02259324  944  cg11213690  1704  cg19897940  2464  cg04597433  3224  cg03464573  3984  cg00411413  185  cg02281662  945  cg11231434  1705  cg19901801  2465  cg04623265  3225  cg03698009  3985  cg00423443  186  cg02283366  946  cg11241541  1706  cg19912142  2466  cg04638205  3226  cg03987115  3986  cg00806490  187  cg02285791  947  cg11254573  1707  cg19923650  2467  cg04651781  3227  cg04298953  3987  cg01090433  188  cg02300154  948  cg11260046  1708  cg19924619  2468  cg04652097  3228  cg05027336  3988  cg01093138  189  cg02303068  949  cg11267630  1709  cg19958627  2469  cg04672706  3229  cg05250768  3989  cg01301138  190  cg02311374  950  cg11267829  1710  cg19961228  2470  cg04743758  3230  cg05490659  3990  cg01396387  191  cg02340083  951  cg11270393  1711  cg19971716  2471  cg04751631  3231  cg07483304  3991  cg01750200  192  cg02372889  952  cg11324957  1712  cg19981568  2472  cg04799343  3232  cg08362210  3992  cg01880569  193  cg02374745  953  cg11334771  1713  cg19987768  2473  cg04849541  3233  cg08938793  3993  cg01935413  194  cg02381279  954  cg11347582  1714  cg19997502  2474  cg04851314  3234  cg08964780  3994  cg01973778  195  cg02387326  955  cg11355215  1715  cg20014398  2475  cg04897892  3235  cg09411999  3995  cg02069674  196  cg02391713  956  cg11356247  1716  cg20030796  2476  cg04945331  3236  cg11097541  3996  cg02282041  197  cg02401454  957  cg11359133  1717  cg20034792  2477  cg04963514  3237  cg13703049  3997  cg02283042  198  cg02435495  958  cg11404502  1718  cg20041567  2478  cg05047401  3238  cg14649140  3998  cg02289020  199  cg02443967  959  cg11413039  1719  cg20065768  2479  cg05065989  3239  cg14780416  3999  cg02495250  200  cg02457680  960  cg11421768  1720  cg20072171  2480  cg05080154  3240  cg14935646  4000  cg02738205  201  cg02460251  961  cg11433622  1721  cg20072442  2481  cg05095591  3241  cg15506609  4001  cg03011928  202  cg02467990  962  cg11436025  1722  cg20079899  2482  cg05134015  3242  cg15912800  4002  cg03474070  203  cg02474799  963  cg11437784  1723  cg20104341  2483  cg05174942  3243  cg16447012  4003  cg03632782  204  cg02478172  964  cg11445123  1724  cg20113824  2484  cg05191879  3244  cg16913789  4004  cg05374412  205  cg02478828  965  cg11453719  1725  cg20114732  2485  cg05221057  3245  cg16967880  4005  cg05453434  206  cg02486253  966  cg11492063  1726  cg20146541  2486  cg05223720  3246  cg18181034  4006  cg05847519  207  cg02503159  967  cg11498607  1727  cg20168806  2487  cg05232914  3247  cg18243072  4007  cg05852523  208  cg02523824  968  cg11519760  1728  cg20170533  2488  cg05238769  3248  cg18311537  4008  cg05949171  209  cg02527669  969  cg11536474  1729  cg20183619  2489  cg05241461  3249  cg18416576  4009  cg07092029  210  cg02534163  970  cg11546137  1730  cg20186067  2490  cg05255275  3250  cg19351701  4010  cg07132650  211  cg02571816  971  cg11561737  1731  cg20194314  2491  cg05268203  3251  cg20399871  4011  cg07301944  212  cg02576468  972  cg11564981  1732  cg20291855  2492  cg05270344  3252  cg20741169  4012  cg08271366  213  cg02616315  973  cg11597131  1733  cg20302133  2493  cg05343184  3253  cg20884887  4013  cg08497530  214  cg02623991  974  cg11601252  1734  cg20308663  2494  cg05355225  3254  cg21001184  4014  cg08518101  215  cg02633723  975  cg11638921  1735  cg20329153  2495  cg05446629  3255  cg21007852  4015  cg08747377  202224094 24 No.  DMP ID  No.  DMP ID  No.  DMP ID  No.  DMP ID  No.  DMP ID  No.  DMP ID  216  cg02644510  976  cg11642106  1736  cg20340346  2496  cg05492975  3256  cg21172377  4016  cg08856946  217  cg02653559  977  cg11660826  1737  cg20370678  2497  cg05523911  3257  cg21942490  4017  cg08977371  218  cg02683759  978  cg11666040  1738  cg20386316  2498  cg05585513  3258  cg22055728  4018  cg09189772  219  cg02694427  979  cg11667020  1739  cg20391058  2499  cg05632088  3259  cg24884519  4019  cg09415485  220  cg02700891  980  cg11686819  1740  cg20395967  2500  cg05635754  3260  cg25188395  4020  cg09441904  221  cg02709432  981  cg11694519  1741  cg20399509  2501  cg05646373  3261  cg25644556  4021  cg09765297  222  cg02710296  982  cg11712990  1742  cg20399616  2502  cg05736768  3262  cg25999578  4022  cg09825093  223  cg02725370  983  cg11716106  1743  cg20407483  2503  cg05764691  3263  cg26259537  4023  cg10148614  224  cg02767771  984  cg11725972  1744  cg20431848  2504  cg05766802  3264  cg27009703  4024  cg10495227  225  cg02772121  985  cg11755933  1745  cg20438306  2505  cg05770238  3265  cg27157482  4025  cg16387516  226  cg02776664  986  cg11764900  1746  cg20443254  2506  cg05858889  3266  cg00870179  4026  cg16494747  227  cg02798576  987  cg11789612  1747  cg20449590  2507  cg05884032  3267  cg01078824  4027  cg19369556  228  cg02801786  988  cg11792470  1748  cg20463526  2508  cg05930881  3268  cg04959634  4028  cg19854301  229  cg02809591  989  cg11803843  1749  cg20512711  2509  cg05937737  3269  cg05092861  4029  cg26610739  230  cg02809746  990  cg11805669  1750  cg20527270  2510  cg05988964  3270  cg05210501  4030  cg26709234  231  cg02846648  991  cg11823511  1751  cg20555674  2511  cg06109379  3271  cg05517976  4031  cg26735980  232  cg02861380  992  cg11827910  1752  cg20558091  2512  cg06123396  3272  cg08575233  4032  cg27088726  233  cg02866628  993  cg11854928  1753  cg20567847  2513  cg06264868  3273  cg09636715  4033  cg27445072  234  cg02874376  994  cg11856078  1754  cg20585869  2514  cg06299284  3274  cg10724867  4034  cg00339556  235  cg02878244  995  cg11862144  1755  cg20610452  2515  cg06314333  3275  cg14188840  4035  cg01791874  236  cg02885519  996  cg11863717  1756  cg20648847  2516  cg06360427  3276  cg15864691  4036  cg03477332  237  cg02898539  997  cg11878331  1757  cg20649017  2517  cg06370771  3277  cg17047659  4037  cg03829734  238  cg02916102  998  cg11893698  1758  cg20668644  2518  cg06411724  3278  cg00644317  4038  cg06782035  239  cg02943578  999  cg11898486  1759  cg20691436  2519  cg06412320  3279  cg01363170  4039  cg09017434  240  cg02966841  1000  cg11901043  1760  cg20699586  2520  cg06425919  3280  cg02366798  4040  cg11584519  241  cg02991338  1001  cg11909137  1761  cg20718350  2521  cg06464008  3281  cg02587624  4041  cg15015920  242  cg03011535  1002  cg11912765  1762  cg20723355  2522  cg06496344  3282  cg03107888  4042  cg16182986  243  cg03032214  1003  cg11940285  1763  cg20744163  2523  cg06572420  3283  cg06397837  4043  cg17507952  244  cg03044249  1004  cg11957331  1764  cg20750832  2524  cg06611810  3284  cg06606213  4044  cg23479922  245  cg03048654  1005  cg11986813  1765  cg20755170  2525  cg06651311  3285  cg07083464  4045  cg25092681  246  cg03053875  1006  cg12014181  1766  cg20776829  2526  cg06666008  3286  cg09554509  4046  cg00504341  247  cg03078269  1007  cg12042659  1767  cg20810478  2527  cg06710082  3287  cg10883303  4047  cg00692462  248  cg03078363  1008  cg12070159  1768  cg20844851  2528  cg06719334  3288  cg11706983  4048  cg00859330  249  cg03117053  1009  cg12071888  1769  cg20852851  2529  cg06777472  3289  cg14922886  4049  cg00979527  250  cg03117976  1010  cg12072262  1770  cg20860472  2530  cg06779449  3290  cg16701896  4050  cg02482718  251  cg03130910  1011  cg12079322  1771  cg20872937  2531  cg06782686  3291  cg19559519  4051  cg02483484  252  cg03131298  1012  cg12099952  1772  cg20892260  2532  cg06794543  3292  cg21332500  4052  cg02771577  253  cg03132824  1013  cg12118269  1773  cg20928945  2533  cg06799422  3293  cg23424766  4053  cg02837536  254  cg03146625  1014  cg12134633  1774  cg20930366  2534  cg06801941  3294  cg25127444  4054  cg03124858  255  cg03161803  1015  cg12143789  1775  cg20935165  2535  cg06832985  3295  cg25576818  4055  cg04027805  256  cg03166753  1016  cg12161228  1776  cg20972294  2536  cg06884470  3296  cg26512254  4056  cg04292104  257  cg03167844  1017  cg12161887  1777  cg20980783  2537  cg06933697  3297  cg00123055  4057  cg05139761  258  cg03169557  1018  cg12162138  1778  cg20985450  2538  cg06967998  3298  cg02222728  4058  cg06929152  259  cg03171770  1019  cg12170314  1779  cg20987924  2539  cg06968859  3299  cg02919422  4059  cg08159291  202224094 25 No.  DMP ID  No.  DMP ID  No.  DMP ID  No.  DMP ID  No.  DMP ID  No.  DMP ID  260  cg03181248  1020  cg12172441  1780  cg21001198  2540  cg06969287  3300  cg03329976  4060  cg09175749  261  cg03184290  1021  cg12174804  1781  cg21026830  2541  cg06972389  3301  cg08044097  4061  cg10222674  262  cg03192598  1022  cg12205822  1782  cg21038156  2542  cg06992285  3302  cg09626193  4062  cg10400362  263  cg03199564  1023  cg12206199  1783  cg21039708  2543  cg07009376  3303  cg11214140  4063  cg11380667  264  cg03202804  1024  cg12260798  1784  cg21042456  2544  cg07065111  3304  cg12883523  4064  cg11735846  265  cg03204678  1025  cg12268236  1785  cg21046148  2545  cg07090701  3305  cg15377283  4065  cg11791914  266  cg03205103  1026  cg12317414  1786  cg21054521  2546  cg07109490  3306  cg15710198  4066  cg11835068  267  cg03217795  1027  cg12353207  1787  cg21063722  2547  cg07124687  3307  cg16830930  4067  cg11926510  268  cg03224572  1028  cg12368188  1788  cg21079345  2548  cg07139762  3308  cg24891539  4068  cg12058478  269  cg03239552  1029  cg12374721  1789  cg21087137  2549  cg07147166  3309  cg25923240  4069  cg12065138  270  cg03257575  1030  cg12382902  1790  cg21093192  2550  cg07152216  3310  cg00577935  4070  cg12631713  271  cg03262260  1031  cg12387154  1791  cg21146652  2551  cg07264634  3311  cg01240931  4071  cg12665669  272  cg03276408  1032  cg12391352  1792  cg21167716  2552  cg07329360  3312  cg01528425  4072  cg13056990  273  cg03278146  1033  cg12412531  1793  cg21183523  2553  cg07395941  3313  cg02511809  4073  cg13480658  274  cg03297163  1034  cg12419766  1794  cg21185289  2554  cg07411620  3314  cg03667968  4074  cg13503382  275  cg03301200  1035  cg12421755  1795  cg21195256  2555  cg07416383  3315  cg04011030  4075  cg13931996  276  cg03306374  1036  cg12435415  1796  cg21199093  2556  cg07448060  3316  cg04226363  4076  cg14218042  277  cg03323696  1037  cg12456714  1797  cg21200408  2557  cg07476508  3317  cg08512345  4077  cg15088574  278  cg03340649  1038  cg12457909  1798  cg21215550  2558  cg07478468  3318  cg08571859  4078  cg15198793  279  cg03352106  1039  cg12468774  1799  cg21222178  2559  cg07489048  3319  cg08934600  4079  cg15580684  280  cg03401357  1040  cg12483476  1800  cg21239311  2560  cg07496545  3320  cg11057897  4080  cg15605704  281  cg03405909  1041  cg12483545  1801  cg21264189  2561  cg07557260  3321  cg11479000  4081  cg16360868  282  cg03419885  1042  cg12500879  1802  cg21277995  2562  cg07568233  3322  cg11613015  4082  cg16386806  283  cg03420866  1043  cg12505170  1803  cg21282630  2563  cg07636194  3323  cg12534150  4083  cg17525406  284  cg03457729  1044  cg12595013  1804  cg21306240  2564  cg07682547  3324  cg14479889  4084  cg17741689  285  cg03475285  1045  cg12598524  1805  cg21319323  2565  cg07691152  3325  cg14511739  4085  cg19628481  286  cg03494430  1046  cg12600174  1806  cg21334513  2566  cg07716946  3326  cg15020645  4086  cg19760464  287  cg03502002  1047  cg12606911  1807  cg21342392  2567  cg07810039  3327  cg16481008  4087  cg19821682  288  cg03506640  1048  cg12615761  1808  cg21383810  2568  cg07838427  3328  cg16970232  4088  cg20624157  289  cg03522247  1049  cg12702981  1809  cg21384402  2569  cg07944396  3329  cg18315896  4089  cg20959866  290  cg03524083  1050  cg12743248  1810  cg21385746  2570  cg07949720  3330  cg18536802  4090  cg21159274  291  cg03530754  1051  cg12744820  1811  cg21392341  2571  cg07990546  3331  cg20311501  4091  cg21267167  292  cg03532926  1052  cg12783819  1812  cg21453451  2572  cg08000065  3332  cg21634602  4092  cg21386545  293  cg03562044  1053  cg12812583  1813  cg21462633  2573  cg08013557  3333  cg22035501  4093  cg21913897  294  cg03563308  1054  cg12816961  1814  cg21463349  2574  cg08036764  3334  cg23497707  4094  cg22025570  295  cg03576469  1055  cg12824796  1815  cg21463368  2575  cg08074851  3335  cg23938220  4095  cg22367872  296  cg03582419  1056  cg12828075  1816  cg21472506  2576  cg08097817  3336  cg24332422  4096  cg22687211  297  cg03602212  1057  cg12853633  1817  cg21472517  2577  cg08107689  3337  cg25922032  4097  cg23015920  298  cg03602280  1058  cg12877723  1818  cg21484228  2578  cg08126203  3338  cg26660754  4098  cg24019371  299  cg03604011  1059  cg12886862  1819  cg21488538  2579  cg08160063  3339  cg00718440  4099  cg24350011  300  cg03637878  1060  cg12892506  1820  cg21497990  2580  cg08180884  3340  cg03079681  4100  cg24525286  301  cg03657573  1061  cg12907379  1821  cg21502786  2581  cg08185105  3341  cg04026675  4101  cg24639469  302  cg03659519  1062  cg12915892  1822  cg21523564  2582  cg08247552  3342  cg07562918  4102  cg24694502  303  cg03679755  1063  cg12926938  1823  cg21539981  2583  cg08283882  3343  cg10848754  4103  cg25198584  202224094 26 No.  DMP ID  No.  DMP ID  No.  DMP ID  No.  DMP ID  No.  DMP ID  No.  DMP ID  304  cg03691144  1064  cg12928379  1824  cg21544698  2584  cg08300419  3344  cg13601799  4104  cg25552937  305  cg03692651  1065  cg12934371  1825  cg21546671  2585  cg08305436  3345  cg14069088  4105  cg26353694  306  cg03700449  1066  cg12974388  1826  cg21549195  2586  cg08320225  3346  cg14430974  4106  cg26435172  307  cg03704006  1067  cg12975230  1827  cg21587238  2587  cg08368617  3347  cg01228636  4107  cg26525076  308  cg03712965  1068  cg12993163  1828  cg21607700  2588  cg08387538  3348  cg01354923  4108  cg26599630  309  cg03714619  1069  cg13012916  1829  cg21624902  2589  cg08393041  3349  cg02261018  4109  cg26662102  310  cg03730533  1070  cg13019491  1830  cg21629500  2590  cg08393317  3350  cg02307823  4110  cg00364611  311  cg03731268  1071  cg13021333  1831  cg21667878  2591  cg08409113  3351  cg03214660  4111  cg00881552  312  cg03738025  1072  cg13023623  1832  cg21678312  2592  cg08445802  3352  cg03236184  4112  cg01033209  313  cg03758150  1073  cg13031251  1833  cg21684012  2593  cg08455778  3353  cg03588460  4113  cg01172965  314  cg03774514  1074  cg13035743  1834  cg21697851  2594  cg08461949  3354  cg03891929  4114  cg02136132  315  cg03863756  1075  cg13045134  1835  cg21707187  2595  cg08475953  3355  cg04059318  4115  cg05182249  316  cg03867465  1076  cg13046832  1836  cg21729992  2596  cg08479865  3356  cg04582473  4116  cg05330297  317  cg03867475  1077  cg13089599  1837  cg21743907  2597  cg08487063  3357  cg04616691  4117  cg09448946  318  cg03877418  1078  cg13090478  1838  cg21762788  2598  cg08499046  3358  cg04638773  4118  cg12212555  319  cg03885271  1079  cg13096208  1839  cg21769702  2599  cg08513547  3359  cg04707787  4119  cg13200664  320  cg03899721  1080  cg13117164  1840  cg21773872  2600  cg08524803  3360  cg04738091  4120  cg13509849  321  cg03900143  1081  cg13159929  1841  cg21779611  2601  cg08546107  3361  cg04824711  4121  cg18306625  322  cg03930313  1082  cg13177747  1842  cg21790626  2602  cg08668790  3362  cg05947570  4122  cg18499667  323  cg03940848  1083  cg13180315  1843  cg21819468  2603  cg08781140  3363  cg06466203  4123  cg19331426  324  cg03943218  1084  cg13198321  1844  cg21821231  2604  cg08796240  3364  cg06731059  4124  cg19584875  325  cg03949284  1085  cg13211683  1845  cg21851351  2605  cg08883223  3365  cg06947206  4125  cg20023155  326  cg03964958  1086  cg13215579  1846  cg21858255  2606  cg08985530  3366  cg07263825  4126  cg21191365  327  cg03970036  1087  cg13222752  1847  cg21865533  2607  cg09017619  3367  cg07655693  4127  cg21231789  328  cg03981954  1088  cg13239420  1848  cg21875802  2608  cg09134205  3368  cg08363193  4128  cg22669058  329  cg04004158  1089  cg13257636  1849  cg21884231  2609  cg09141856  3369  cg08602305  4129  cg22819502  330  cg04008888  1090  cg13261536  1850  cg21901718  2610  cg09159285  3370  cg08859916  4130  cg23900774  331  cg04021697  1091  cg13267264  1851  cg21908235  2611  cg09403666  3371  cg08960754  4131  cg25225073  332  cg04023150  1092  cg13283952  1852  cg21996149  2612  cg09433131  3372  cg08995089  4132  cg25874421  333  cg04034767  1093  cg13291704  1853  cg21996227  2613  cg09478478  3373  cg09472211  4133  cg25942631  334  cg04037038  1094  cg13294849  1854  cg22052659  2614  cg09481404  3374  cg09528884  4134  cg00735962  335  cg04097639  1095  cg13298199  1855  cg22061831  2615  cg09558195  3375  cg09550257  4135  cg00795205  336  cg04109898  1096  cg13300273  1856  cg22098115  2616  cg09639151  3376  cg10041390  4136  cg01661235  337  cg04111071  1097  cg13314145  1857  cg22115892  2617  cg09642925  3377  cg10205334  4137  cg03156893  338  cg04115680  1098  cg13320291  1858  cg22125968  2618  cg09645574  3378  cg10930218  4138  cg03503785  339  cg04118306  1099  cg13324546  1859  cg22156700  2619  cg09649610  3379  cg12005026  4139  cg03973705  340  cg04123776  1100  cg13352750  1860  cg22158650  2620  cg09658429  3380  cg13528847  4140  cg04029168  341  cg04140663  1101  cg13356896  1861  cg22158769  2621  cg09683350  3381  cg13885325  4141  cg04086239  342  cg04150495  1102  cg13358636  1862  cg22167515  2622  cg09685182  3382  cg15412736  4142  cg04279973  343  cg04172166  1103  cg13368519  1863  cg22178613  2623  cg09797337  3383  cg16404460  4143  cg05120716  344  cg04176888  1104  cg13390867  1864  cg22191696  2624  cg09803951  3384  cg16443434  4144  cg05616819  345  cg04178787  1105  cg13404421  1865  cg22195627  2625  cg09919570  3385  cg16686761  4145  cg05632631  346  cg04204831  1106  cg13422275  1866  cg22260952  2626  cg09966455  3386  cg16687447  4146  cg05944877  347  cg04209913  1107  cg13434638  1867  cg22274539  2627  cg09972405  3387  cg17083429  4147  cg06401532  202224094 27 No.  DMP ID  No.  DMP ID  No.  DMP ID  No.  DMP ID  No.  DMP ID  No.  DMP ID  348  cg04214938  1108  cg13437581  1868  cg22352818  2628  cg09974041  3388  cg17114151  4148  cg07959068  349  cg04223424  1109  cg13438893  1869  cg22356339  2629  cg09975620  3389  cg17489897  4149  cg08327371  350  cg04224064  1110  cg13445796  1870  cg22376822  2630  cg10021878  3390  cg17557106  4150  cg08944430  351  cg04228935  1111  cg13457172  1871  cg22396555  2631  cg10042106  3391  cg18141918  4151  cg09031790  352  cg04262140  1112  cg13459498  1872  cg22399133  2632  cg10216717  3392  cg18384060  4152  cg09108394  353  cg04281464  1113  cg13465477  1873  cg22421859  2633  cg10259701  3393  cg18665732  4153  cg09305491  354  cg04294888  1114  cg13475583  1874  cg22434835  2634  cg10296410  3394  cg18819818  4154  cg09327847  355  cg04317962  1115  cg13476133  1875  cg22455914  2635  cg10305789  3395  cg18953873  4155  cg09507526  356  cg04320956  1116  cg13481132  1876  cg22457668  2636  cg10374084  3396  cg19358349  4156  cg21370856  357  cg04339692  1117  cg13482308  1877  cg22460081  2637  cg10386483  3397  cg19634213  4157  cg24250393  358  cg04347874  1118  cg13486532  1878  cg22471726  2638  cg10445315  3398  cg19659388  4158  cg26562691  359  cg04360793  1119  cg13488570  1879  cg22473620  2639  cg10541517  3399  cg20337093  4159  cg26685404  360  cg04362790  1120  cg13492692  1880  cg22474464  2640  cg10541864  3400  cg20849549  4160  cg02191312  361  cg04368094  1121  cg13495205  1881  cg22475974  2641  cg10574843  3401  cg21480743  4161  cg05887153  362  cg04370314  1122  cg13502741  1882  cg22491927  2642  cg10671668  3402  cg21573601  4162  cg08504659  363  cg04399751  1123  cg13530938  1883  cg22498143  2643  cg10699986  3403  cg22564317  4163  cg09516965  364  cg04401986  1124  cg13533340  1884  cg22511877  2644  cg10726559  3404  cg23149470  4164  cg10837806  365  cg04402007  1125  cg13539545  1885  cg22512438  2645  cg10739556  3405  cg23753021  4165  cg13561855  366  cg04407470  1126  cg13545212  1886  cg22538054  2646  cg10754395  3406  cg25452974  4166  cg17929687  367  cg04413782  1127  cg13546240  1887  cg22541735  2647  cg10785263  3407  cg26090855  4167  cg18242103  368  cg04414975  1128  cg13547712  1888  cg22549870  2648  cg10836101  3408  cg26127345  4168  cg18369034  369  cg04415798  1129  cg13579167  1889  cg22557662  2649  cg10858215  3409  cg27084903  4169  cg19650253  370  cg04418647  1130  cg13592399  1890  cg22579265  2650  cg10861722  3410  cg27299538  4170  cg19716643  371  cg04425920  1131  cg13596833  1891  cg22598028  2651  cg10863741  3411  cg27422496  4171  cg23481279  372  cg04452959  1132  cg13601435  1892  cg22616881  2652  cg10880203  3412  cg01756564  4172  cg24089118  373  cg04475027  1133  cg13611347  1893  cg22617773  2653  cg10965117  3413  cg01800843  4173  cg24989962  374  cg04496304  1134  cg13631572  1894  cg22620090  2654  cg10972973  3414  cg01991180  4174  cg26168772  375  cg04507515  1135  cg13636096  1895  cg22620221  2655  cg10976626  3415  cg02105423  4175  cg27131955  376  cg04515996  1136  cg13645732  1896  cg22669623  2656  cg11176990  3416  cg02511767  4176  cg27634876  377  cg04521510  1137  cg13651690  1897  cg22674699  2657  cg11229513  3417  cg03165700  4177  cg00414292  378  cg04522310  1138  cg13659360  1898  cg22694191  2658  cg11268834  3418  cg03569616  4178  cg05013728  379  cg04534765  1139  cg13670316  1899  cg22702772  2659  cg11273848  3419  cg04709886  4179  cg05835982  380  cg04543008  1140  cg13677149  1900  cg22714290  2660  cg11328303  3420  cg04770025  4180  cg14595003  381  cg04549333  1141  cg13678973  1901  cg22715837  2661  cg11379081  3421  cg04826772  4181  cg15109144  382  cg04550737  1142  cg13683990  1902  cg22723502  2662  cg11416384  3422  cg05033322  4182  cg17173166  383  cg04564920  1143  cg13686537  1903  cg22731271  2663  cg11452391  3423  cg05231509  4183  cg21217577  384  cg04575395  1144  cg13691247  1904  cg22732101  2664  cg11469061  3424  cg05471373  4184  cg22931604  385  cg04612444  1145  cg13692446  1905  cg22747076  2665  cg11497372  3425  cg05637308  4185  cg01244124  386  cg04633922  1146  cg13699355  1906  cg22747746  2666  cg11500790  3426  cg06053805  4186  cg01918043  387  cg04638468  1147  cg13703089  1907  cg22749589  2667  cg11502555  3427  cg06081482  4187  cg08815652  388  cg04665124  1148  cg13703871  1908  cg22758454  2668  cg11557382  3428  cg06750635  4188  cg09272849  389  cg04670802  1149  cg13721404  1909  cg22759823  2669  cg11585071  3429  cg08954307  4189  cg09345916  390  cg04682087  1150  cg13755070  1910  cg22763718  2670  cg11656553  3430  cg09808176  4190  cg09353563  391  cg04688351  1151  cg13759674  1911  cg22784954  2671  cg11667086  3431  cg10610482  4191  cg10177766  202224094 28 No.  DMP ID  No.  DMP ID  No.  DMP ID  No.  DMP ID  No.  DMP ID  No.  DMP ID  392  cg04689080  1152  cg13782274  1912  cg22790257  2672  cg11770080  3432  cg10976287  4192  cg11937920  393  cg04698114  1153  cg13791254  1913  cg22795586  2673  cg11793699  3433  cg11588932  4193  cg12642431  394  cg04701034  1154  cg13796823  1914  cg22797031  2674  cg11795854  3434  cg12019961  4194  cg13571319  395  cg04704531  1155  cg13800209  1915  cg22802813  2675  cg11873482  3435  cg12106634  4195  cg14562915  396  cg04706655  1156  cg13819319  1916  cg22830113  2676  cg11889808  3436  cg12139707  4196  cg17098829  397  cg04723401  1157  cg13874287  1917  cg22831607  2677  cg11930554  3437  cg12848864  4197  cg17726266  398  cg04727521  1158  cg13879483  1918  cg22853371  2678  cg12002589  3438  cg14761454  4198  cg17798857  399  cg04728482  1159  cg13886334  1919  cg22868282  2679  cg12062220  3439  cg15370815  4199  cg17886678  400  cg04733537  1160  cg13906377  1920  cg22876812  2680  cg12091642  3440  cg15504467  4200  cg20566885  401  cg04738965  1161  cg13912117  1921  cg22878622  2681  cg12150784  3441  cg16693212  4201  cg21540984  402  cg04739647  1162  cg13916459  1922  cg22881914  2682  cg12193731  3442  cg16788234  4202  cg21897845  403  cg04741094  1163  cg13931925  1923  cg22912497  2683  cg12243597  3443  cg17114932  4203  cg03611452  404  cg04743654  1164  cg13933262  1924  cg22916722  2684  cg12290311  3444  cg17420659  4204  cg04784475  405  cg04764012  1165  cg13958426  1925  cg22940848  2685  cg12378187  3445  cg18042593  4205  cg06940614  406  cg04765848  1166  cg13962212  1926  cg22943986  2686  cg12393275  3446  cg18391757  4206  cg09449030  407  cg04766529  1167  cg13969001  1927  cg22975695  2687  cg12393318  3447  cg18457775  4207  cg10701051  408  cg04786142  1168  cg13974773  1928  cg23003534  2688  cg12439439  3448  cg19288979  4208  cg10710439  409  cg04805181  1169  cg13982529  1929  cg23005797  2689  cg12492087  3449  cg19892525  4209  cg22521696  410  cg04828133  1170  cg13990351  1930  cg23011597  2690  cg12581627  3450  cg20342375  4210  cg22685966  411  cg04842146  1171  cg13997864  1931  cg23019935  2691  cg12584111  3451  cg21681962  4211  cg24851318  412  cg04842426  1172  cg14000361  1932  cg23023126  2692  cg12601945  3452  cg22477592  4212  cg25324105  413  cg04849842  1173  cg14006515  1933  cg23049458  2693  cg12602633  3453  cg22678707  4213  cg00988227  414  cg04864807  1174  cg14007067  1934  cg23054189  2694  cg12624721  3454  cg22837512  4214  cg01091117  415  cg04904318  1175  cg14019186  1935  cg23064609  2695  cg12631351  3455  cg23275463  4215  cg01897756  416  cg04908077  1176  cg14024461  1936  cg23065934  2696  cg12756396  3456  cg23389069  4216  cg01952088  417  cg04912843  1177  cg14038391  1937  cg23068913  2697  cg12764034  3457  cg24030675  4217  cg02026948  418  cg04915044  1178  cg14052065  1938  cg23069167  2698  cg12781700  3458  cg24568245  4218  cg03337243  419  cg04920358  1179  cg14055896  1939  cg23089825  2699  cg12825070  3459  cg25400013  4219  cg04092800  420  cg04927502  1180  cg14060496  1940  cg23095743  2700  cg12839172  3460  cg25740661  4220  cg04126707  421  cg04927931  1181  cg14065127  1941  cg23097402  2701  cg12840719  3461  cg25918541  4221  cg04727116  422  cg04970570  1182  cg14072016  1942  cg23105338  2702  cg13023870  3462  cg27453365  4222  cg04790357  423  cg04974290  1183  cg14072515  1943  cg23121156  2703  cg13028819  3463  cg27599391  4223  cg04824304  424  cg04976324  1184  cg14080475  1944  cg23144681  2704  cg13242070  3464  cg27627854  4224  cg05971966  425  cg05016408  1185  cg14081667  1945  cg23161999  2705  cg13248778  3465  cg00744656  4225  cg06013215  426  cg05020604  1186  cg14087921  1946  cg23176214  2706  cg13345683  3466  cg00955911  4226  cg06802812  427  cg05020625  1187  cg14093715  1947  cg23179456  2707  cg13441766  3467  cg01662117  4227  cg08164315  428  cg05031521  1188  cg14094983  1948  cg23180938  2708  cg13458645  3468  cg01824511  4228  cg11821200  429  cg05033333  1189  cg14108894  1949  cg23200020  2709  cg13492103  3469  cg01892516  4229  cg13663845  430  cg05052324  1190  cg14118515  1950  cg23205387  2710  cg13499371  3470  cg03015370  4230  cg16104076  431  cg05057720  1191  cg14123923  1951  cg23207990  2711  cg13519035  3471  cg03026462  4231  cg17421097  432  cg05063520  1192  cg14149680  1952  cg23208513  2712  cg13643914  3472  cg03772350  4232  cg19672694  433  cg05090319  1193  cg14156405  1953  cg23217622  2713  cg13644317  3473  cg04932551  4233  cg26597539  434  cg05091238  1194  cg14159026  1954  cg23229261  2714  cg13676706  3474  cg07940072  4234  cg27071460  435  cg05099508  1195  cg14168530  1955  cg23236325  2715  cg13713922  3475  cg09276158  4235  cg01920829  202224094 29 No.  DMP ID  No.  DMP ID  No.  DMP ID  No.  DMP ID  No.  DMP ID  No.  DMP ID  436  cg05151803  1196  cg14169333  1956  cg23241448  2716  cg13784080  3476  cg10323697  4236  cg02614660  437  cg05157140  1197  cg14189141  1957  cg23241781  2717  cg13826890  3477  cg10724086  4237  cg03112382  438  cg05164933  1198  cg14192957  1958  cg23244289  2718  cg13849454  3478  cg10988041  4238  cg03164275  439  cg05166490  1199  cg14200170  1959  cg23244488  2719  cg13877670  3479  cg11260422  4239  cg04778271  440  cg05167251  1200  cg14204619  1960  cg23244790  2720  cg13906823  3480  cg16527491  4240  cg08724891  441  cg05196969  1201  cg14215310  1961  cg23248887  2721  cg13909949  3481  cg16581536  4241  cg10116864  442  cg05211267  1202  cg14223646  1962  cg23253309  2722  cg13939859  3482  cg19802865  4242  cg12156672  443  cg05224741  1203  cg14231297  1963  cg23255835  2723  cg13945749  3483  cg23032032  4243  cg14002622  444  cg05227549  1204  cg14239111  1964  cg23263911  2724  cg14002960  3484  cg23664186  4244  cg14831838  445  cg05241355  1205  cg14248715  1965  cg23274680  2725  cg14022137  3485  cg00960395  4245  cg14910495  446  cg05255522  1206  cg14249876  1966  cg23278196  2726  cg14032033  3486  cg01543654  4246  cg14941457  447  cg05283646  1207  cg14250833  1967  cg23290344  2727  cg14074052  3487  cg04574034  4247  cg15442811  448  cg05296099  1208  cg14262681  1968  cg23302649  2728  cg14148690  3488  cg04618333  4248  cg16531271  449  cg05297854  1209  cg14270857  1969  cg23302682  2729  cg14216068  3489  cg05557449  4249  cg16652741  450  cg05302386  1210  cg14278853  1970  cg23303108  2730  cg14216285  3490  cg08886727  4250  cg16831573  451  cg05306745  1211  cg14287235  1971  cg23318063  2731  cg14224196  3491  cg09302903  4251  cg19451845  452  cg05310764  1212  cg14294859  1972  cg23324953  2732  cg14251870  3492  cg09866983  4252  cg23452259  453  cg05311410  1213  cg14301000  1973  cg23325963  2733  cg14305278  3493  cg13597528  4253  cg26682866  454  cg05336698  1214  cg14302471  1974  cg23353952  2734  cg14353278  3494  cg14230397  4254  cg27638196  455  cg05353872  1215  cg14314029  1975  cg23366979  2735  cg14409023  3495  cg16251357  4255  cg00662556  456  cg05369857  1216  cg14319135  1976  cg23391785  2736  cg14409958  3496  cg17444839  4256  cg00854242  457  cg05372113  1217  cg14343017  1977  cg23400512  2737  cg14425564  3497  cg20094830  4257  cg03165383  458  cg05372242  1218  cg14353137  1978  cg23428985  2738  cg14447710  3498  cg23470850  4258  cg03175653  459  cg05376374  1219  cg14367020  1979  cg23440816  2739  cg14457782  3499  cg25245133  4259  cg05528293  460  cg05391318  1220  cg14383422  1980  cg23448584  2740  cg14473102  3500  cg05260966  4260  cg05896682  461  cg05422029  1221  cg14394692  1981  cg23462956  2741  cg14487131  3501  cg05288803  4261  cg06562865  462  cg05434287  1222  cg14416311  1982  cg23476447  2742  cg14493920  3502  cg05470389  4262  cg07390210  463  cg05437823  1223  cg14416371  1983  cg23495733  2743  cg14496282  3503  cg12498887  4263  cg10390058  464  cg05452406  1224  cg14428146  1984  cg23495748  2744  cg14526718  3504  cg17571207  4264  cg10486998  465  cg05482942  1225  cg14453201  1985  cg23497383  2745  cg14530143  3505  cg20500237  4265  cg12699371  466  cg05485379  1226  cg14458834  1986  cg23522194  2746  cg14533651  3506  cg22687380  4266  cg15129823  467  cg05497345  1227  cg14464551  1987  cg23528400  2747  cg14568830  3507  cg23601468  4267  cg15343119  468  cg05506209  1228  cg14470895  1988  cg23544472  2748  cg14584961  3508  cg24080529  4268  cg15443732  469  cg05513806  1229  cg14486338  1989  cg23603027  2749  cg14597214  3509  cg00248856  4269  cg15484988  470  cg05527869  1230  cg14487665  1990  cg23615741  2750  cg14669379  3510  cg00858899  4270  cg18961944  471  cg05542262  1231  cg14502484  1991  cg23619365  2751  cg14678430  3511  cg00953256  4271  cg19705131  472  cg05542338  1232  cg14507337  1992  cg23643466  2752  cg14696870  3512  cg01390647  4272  cg21634365  473  cg05560435  1233  cg14517004  1993  cg23649708  2753  cg14715697  3513  cg01406280  4273  cg21661027  474  cg05571581  1234  cg14523847  1994  cg23663774  2754  cg14742937  3514  cg02255700  4274  cg26038190  475  cg05583676  1235  cg14550611  1995  cg23690166  2755  cg14777772  3515  cg02694676  4275  cg26721264  476  cg05600740  1236  cg14555045  1996  cg23690893  2756  cg14801669  3516  cg02753511  4276  cg00530740  477  cg05616550  1237  cg14557064  1997  cg23697546  2757  cg14802502  3517  cg03040489  4277  cg01015199  478  cg05649391  1238  cg14558529  1998  cg23712342  2758  cg14817655  3518  cg03364015  4278  cg01145600  479  cg05651243  1239  cg14562712  1999  cg23715830  2759  cg14840848  3519  cg03735308  4279  cg02731193  202224094 30 No.  DMP ID  No.  DMP ID  No.  DMP ID  No.  DMP ID  No.  DMP ID  No.  DMP ID  480  cg05661282  1240  cg14564076  2000  cg23727983  2760  cg14926717  3520  cg04717045  4280  cg02868790  481  cg05663573  1241  cg14564616  2001  cg23729107  2761  cg14931230  3521  cg05068533  4281  cg03440426  482  cg05667348  1242  cg14587524  2002  cg23746497  2762  cg14950169  3522  cg05164185  4282  cg03796751  483  cg05672569  1243  cg14602220  2003  cg23758305  2763  cg14977066  3523  cg05200606  4283  cg04165000  484  cg05710540  1244  cg14603098  2004  cg23806894  2764  cg15012484  3524  cg06539449  4284  cg05961096  485  cg05716724  1245  cg14625175  2005  cg23807890  2765  cg15014975  3525  cg06741896  4285  cg06706183  486  cg05719164  1246  cg14642259  2006  cg23808946  2766  cg15032142  3526  cg07149785  4286  cg08302713  487  cg05726239  1247  cg14654886  2007  cg23817893  2767  cg15049968  3527  cg07295918  4287  cg11792075  488  cg05728754  1248  cg14676272  2008  cg23818870  2768  cg15054725  3528  cg07663571  4288  cg12013321  489  cg05732750  1249  cg14688579  2009  cg23822732  2769  cg15115960  3529  cg07781399  4289  cg12050713  490  cg05735180  1250  cg14699728  2010  cg23829024  2770  cg15160263  3530  cg08170622  4290  cg14029170  491  cg05766140  1251  cg14703002  2011  cg23855505  2771  cg15186181  3531  cg09520904  4291  cg14762984  492  cg05768427  1252  cg14712186  2012  cg23857238  2772  cg15241920  3532  cg09551996  4292  cg14869141  493  cg05783139  1253  cg14719951  2013  cg23881278  2773  cg15278374  3533  cg09637363  4293  cg15407440  494  cg05783915  1254  cg14720951  2014  cg23882862  2774  cg15312264  3534  cg09801353  4294  cg19144949  495  cg05809668  1255  cg14732324  2015  cg23901852  2775  cg15466862  3535  cg10518262  4295  cg19740353  496  cg05821789  1256  cg14754787  2016  cg23906738  2776  cg15488978  3536  cg10539418  4296  cg21436520  497  cg05835105  1257  cg14763548  2017  cg23913421  2777  cg15509687  3537  cg11190277  4297  cg21613175  498  cg05845376  1258  cg14765959  2018  cg23928165  2778  cg15549700  3538  cg11234767  4298  cg23554129  499  cg05860723  1259  cg14768785  2019  cg23930313  2779  cg15623111  3539  cg11398323  4299  cg24906519  500  cg05882680  1260  cg14776321  2020  cg23934404  2780  cg15638709  3540  cg11802013  4300  cg26752263  501  cg05883978  1261  cg14780632  2021  cg23935616  2781  cg15700197  3541  cg12129983  4301  cg01179851  502  cg05904135  1262  cg14781189  2022  cg23989821  2782  cg15778437  3542  cg12263469  4302  cg02193951  503  cg05905176  1263  cg14788768  2023  cg23997405  2783  cg15852352  3543  cg12266049  4303  cg02507889  504  cg05917460  1264  cg14789818  2024  cg24000814  2784  cg16065021  3544  cg12825880  4304  cg02705011  505  cg05923687  1265  cg14805347  2025  cg24011260  2785  cg16104371  3545  cg12994233  4305  cg03712816  506  cg05924540  1266  cg14861089  2026  cg24029994  2786  cg16104384  3546  cg13271751  4306  cg03788215  507  cg05928342  1267  cg14866200  2027  cg24030037  2787  cg16151261  3547  cg13608094  4307  cg04389822  508  cg05940691  1268  cg14871932  2028  cg24031355  2788  cg16276063  3548  cg13720316  4308  cg04988994  509  cg05940984  1269  cg14874750  2029  cg24033558  2789  cg16283362  3549  cg14513281  4309  cg05678191  510  cg05943574  1270  cg14885748  2030  cg24041541  2790  cg16304215  3550  cg14872731  4310  cg06954658  511  cg05945059  1271  cg14897833  2031  cg24045038  2791  cg16337185  3551  cg15233880  4311  cg07382554  512  cg05952494  1272  cg14944647  2032  cg24053265  2792  cg16353508  3552  cg15330584  4312  cg08182407  513  cg05970721  1273  cg14958969  2033  cg24066980  2793  cg16357388  3553  cg15954335  4313  cg10717463  514  cg06045337  1274  cg14979301  2034  cg24080247  2794  cg16385763  3554  cg15974867  4314  cg13634602  515  cg06060135  1275  cg14985989  2035  cg24113266  2795  cg16402270  3555  cg16794682  4315  cg13794993  516  cg06083330  1276  cg14991984  2036  cg24114556  2796  cg16404157  3556  cg16969182  4316  cg15013496  517  cg06100368  1277  cg14996220  2037  cg24127719  2797  cg16405019  3557  cg18773844  4317  cg15191648  518  cg06122871  1278  cg15010213  2038  cg24134504  2798  cg16409261  3558  cg19047670  4318  cg16284437  519  cg06126225  1279  cg15031661  2039  cg24150172  2799  cg16431543  3559  cg19137748  4319  cg16433156  520  cg06173663  1280  cg15044957  2040  cg24154839  2800  cg16483725  3560  cg19209049  4320  cg20980587  521  cg06183338  1281  cg15057061  2041  cg24158594  2801  cg16521643  3561  cg19472759  4321  cg22242857  522  cg06204735  1282  cg15058464  2042  cg24164564  2802  cg16589830  3562  cg19964454  4322  cg23983671  523  cg06215569  1283  cg15079315  2043  cg24199834  2803  cg16653700  3563  cg20195046  4323  cg25891069  202224094 31 No.  DMP ID  No.  DMP ID  No.  DMP ID  No.  DMP ID  No.  DMP ID  No.  DMP ID  524  cg06226675  1284  cg15082028  2044  cg24215159  2804  cg16705627  3564  cg21742931  4324  cg27116888  525  cg06282270  1285  cg15084543  2045  cg24221648  2805  cg16727923  3565  cg21815083  4325  cg22524657  526  cg06282863  1286  cg15092343  2046  cg24234651  2806  cg16761581  3566  cg23753457  4326  cg00155514  527  cg06304097  1287  cg15104644  2047  cg24245418  2807  cg16793394  3567  cg24020398  4327  cg00857660  528  cg06304401  1288  cg15108640  2048  cg24276681  2808  cg16804284  3568  cg24203315  4328  cg02955369  529  cg06312813  1289  cg15122358  2049  cg24278165  2809  cg16884902  3569  cg24387864  4329  cg03044573  530  cg06327407  1290  cg15126544  2050  cg24281267  2810  cg16937268  3570  cg24419164  4330  cg03584783  531  cg06332339  1291  cg15126975  2051  cg24292235  2811  cg16977645  3571  cg25060573  4331  cg04102126  532  cg06332842  1292  cg15131808  2052  cg24304093  2812  cg17008486  3572  cg25395653  4332  cg05396044  533  cg06335867  1293  cg15132565  2053  cg24311564  2813  cg17030173  3573  cg25611369  4333  cg06189265  534  cg06355129  1294  cg15140703  2054  cg24328125  2814  cg17034390  3574  cg26399164  4334  cg06644515  535  cg06371502  1295  cg15146859  2055  cg24336989  2815  cg17046586  3575  cg27021553  4335  cg06704773  536  cg06379876  1296  cg15173134  2056  cg24368848  2816  cg17094249  3576  cg04181079  4336  cg07177756  537  cg06382344  1297  cg15205636  2057  cg24377694  2817  cg17144184  3577  cg13802966  4337  cg08947084  538  cg06392169  1298  cg15215348  2058  cg24390913  2818  cg17200768  3578  cg21002651  4338  cg09058860  539  cg06404175  1299  cg15215612  2059  cg24415208  2819  cg17204129  3579  cg01886855  4339  cg10578779  540  cg06424065  1300  cg15219228  2060  cg24425021  2820  cg17214381  3580  cg02643667  4340  cg11537707  541  cg06427821  1301  cg15221604  2061  cg24427504  2821  cg17228232  3581  cg06099014  4341  cg13489958  542  cg06434454  1302  cg15222899  2062  cg24430140  2822  cg17276590  3582  cg18729973  4342  cg16290996  543  cg06444282  1303  cg15251385  2063  cg24452128  2823  cg17283453  3583  cg19247032  4343  cg16905926  544  cg06445348  1304  cg15261247  2064  cg24454144  2824  cg17338430  3584  cg22438247  4344  cg17025683  545  cg06463958  1305  cg15267232  2065  cg24471254  2825  cg17384380  3585  cg24606807  4345  cg17170111  546  cg06471596  1306  cg15272362  2066  cg24495585  2826  cg17448335  3586  cg27405706  4346  cg17868533  547  cg06490869  1307  cg15285250  2067  cg24504927  2827  cg17486097  3587  cg00332048  4347  cg19406762  548  cg06495961  1308  cg15300436  2068  cg24511738  2828  cg17509220  3588  cg02195995  4348  cg20781819  549  cg06499647  1309  cg15305070  2069  cg24530250  2829  cg17514558  3589  cg02301805  4349  cg21770828  550  cg06506966  1310  cg15316843  2070  cg24563094  2830  cg17529832  3590  cg02370815  4350  cg25883402  551  cg06515144  1311  cg15326755  2071  cg24595510  2831  cg17546215  3591  cg03260621  4351  cg00237904  552  cg06518327  1312  cg15368905  2072  cg24599434  2832  cg17588266  3592  cg04892643  4352  cg01539474  553  cg06530338  1313  cg15382538  2073  cg24604013  2833  cg17619993  3593  cg05684907  4353  cg01585333  554  cg06530490  1314  cg15384383  2074  cg24613080  2834  cg17621718  3594  cg05865493  4354  cg01895612  555  cg06537894  1315  cg15384598  2075  cg24624901  2835  cg17628556  3595  cg06230668  4355  cg01977486  556  cg06546806  1316  cg15386350  2076  cg24625136  2836  cg17657322  3596  cg06962918  4356  cg02657360  557  cg06550539  1317  cg15396686  2077  cg24641302  2837  cg17757602  3597  cg06977285  4357  cg02694715  558  cg06558014  1318  cg15407505  2078  cg24645214  2838  cg17760405  3598  cg07513622  4358  cg02864690  559  cg06572465  1319  cg15415452  2079  cg24680586  2839  cg17807172  3599  cg08146609  4359  cg02886509  560  cg06594404  1320  cg15425541  2080  cg24685755  2840  cg17839721  3600  cg08285151  4360  cg03175030  561  cg06611922  1321  cg15427886  2081  cg24689061  2841  cg17858500  3601  cg08426157  4361  cg03996735  562  cg06616729  1322  cg15428435  2082  cg24720571  2842  cg17861455  3602  cg08725366  4362  cg04088212  563  cg06629130  1323  cg15467646  2083  cg24747866  2843  cg17877704  3603  cg09494378  4363  cg04647234  564  cg06632207  1324  cg15484532  2084  cg24755177  2844  cg17932055  3604  cg10068437  4364  cg04817190  565  cg06633438  1325  cg15490715  2085  cg24761507  2845  cg17949727  3605  cg11321459  4365  cg04975775  566  cg06653045  1326  cg15497761  2086  cg24808280  2846  cg18118147  3606  cg11765288  4366  cg06197492  567  cg06679334  1327  cg15556502  2087  cg24812837  2847  cg18159323  3607  cg12081743  4367  cg06749854  202224094 32 No.  DMP ID  No.  DMP ID  No.  DMP ID  No.  DMP ID  No.  DMP ID  No.  DMP ID  568  cg06721601  1328  cg15558061  2088  cg24831391  2848  cg18161327  3608  cg13420273  4368  cg06765785  569  cg06740600  1329  cg15564098  2089  cg24833737  2849  cg18290848  3609  cg15014369  4369  cg07342901  570  cg06747432  1330  cg15565065  2090  cg24838949  2850  cg18323912  3610  cg15952586  4370  cg09452478  571  cg06769546  1331  cg15576900  2091  cg24843380  2851  cg18339788  3611  cg16469740  4371  cg09701145  572  cg06785999  1332  cg15613420  2092  cg24848035  2852  cg18351939  3612  cg16475478  4372  cg10154633  573  cg06802522  1333  cg15617155  2093  cg24878868  2853  cg18375860  3613  cg16803837  4373  cg10602543  574  cg06807993  1334  cg15634980  2094  cg24880701  2854  cg18405691  3614  cg16925459  4374  cg11492040  575  cg06809252  1335  cg15659713  2095  cg24884444  2855  cg18486102  3615  cg17419514  4375  cg11716026  576  cg06817490  1336  cg15750941  2096  cg24884703  2856  cg18488157  3616  cg18856632  4376  cg11735853  577  cg06818532  1337  cg15790037  2097  cg24886257  2857  cg18505593  3617  cg18885392  4377  cg11753499  578  cg06829686  1338  cg15804426  2098  cg24887265  2858  cg18557131  3618  cg19585556  4378  cg13210239  579  cg06847006  1339  cg15811515  2099  cg24892966  2859  cg18639233  3619  cg19969359  4379  cg13581483  580  cg06847624  1340  cg15836635  2100  cg24909548  2860  cg18646207  3620  cg20648975  4380  cg14937069  581  cg06852942  1341  cg15848890  2101  cg24928391  2861  cg18674980  3621  cg21433125  4381  cg15269875  582  cg06875598  1342  cg15854847  2102  cg24946597  2862  cg18693395  3622  cg22750906  4382  cg15317267  583  cg06898823  1343  cg15885337  2103  cg24960947  2863  cg18693673  3623  cg23074799  4383  cg15394860  584  cg06916239  1344  cg15896182  2104  cg24977670  2864  cg18723937  3624  cg23385718  4384  cg15886040  585  cg06937491  1345  cg15908367  2105  cg24980653  2865  cg18866015  3625  cg24350771  4385  cg15922305  586  cg06945523  1346  cg15959252  2106  cg24995678  2866  cg18881873  3626  cg24458314  4386  cg15963714  587  cg06945936  1347  cg15975865  2107  cg25000021  2867  cg18925726  3627  cg25042284  4387  cg16153294  588  cg06962177  1348  cg15985184  2108  cg25020286  2868  cg18940047  3628  cg25620356  4388  cg16303279  589  cg06962944  1349  cg15987088  2109  cg25022271  2869  cg18944047  3629  cg00355281  4389  cg16574793  590  cg06966242  1350  cg15994026  2110  cg25026529  2870  cg19043574  3630  cg01050885  4390  cg16675558  591  cg06996389  1351  cg16001495  2111  cg25032595  2871  cg19178853  3631  cg02484210  4391  cg17769238  592  cg06998282  1352  cg16005540  2112  cg25051341  2872  cg19193155  3632  cg04697148  4392  cg17985533  593  cg06999799  1353  cg16021909  2113  cg25078444  2873  cg19194373  3633  cg05158615  4393  cg18104242  594  cg07014673  1354  cg16073378  2114  cg25092838  2874  cg19317211  3634  cg11475550  4394  cg18362496  595  cg07037412  1355  cg16086620  2115  cg25103726  2875  cg19351026  3635  cg11892240  4395  cg18454954  596  cg07078225  1356  cg16100355  2116  cg25115460  2876  cg19370054  3636  cg12614105  4396  cg18511798  597  cg07099331  1357  cg16104915  2117  cg25135457  2877  cg19600750  3637  cg15929698  4397  cg19024989  598  cg07113230  1358  cg16126280  2118  cg25136495  2878  cg19659741  3638  cg18106668  4398  cg19943238  599  cg07113642  1359  cg16150752  2119  cg25143990  2879  cg19801921  3639  cg18119803  4399  cg20891060  600  cg07115542  1360  cg16166796  2120  cg25147376  2880  cg19813015  3640  cg21097881  4400  cg21167159  601  cg07132187  1361  cg16178603  2121  cg25160286  2881  cg19868631  3641  cg24242823  4401  cg22172494  602  cg07137955  1362  cg16192707  2122  cg25191041  2882  cg19870512  3642  cg24885417  4402  cg22259242  603  cg07139301  1363  cg16201038  2123  cg25191628  2883  cg19883384  3643  cg00839584  4403  cg23476401  604  cg07142797  1364  cg16201883  2124  cg25200152  2884  cg19968840  3644  cg20548977  4404  cg23977670  605  cg07143418  1365  cg16202470  2125  cg25209132  2885  cg20008332  3645  cg27083787  4405  cg24409677  606  cg07149609  1366  cg16206460  2126  cg25209842  2886  cg20014049  3646  cg27606396  4406  cg24510613  607  cg07150062  1367  cg16215203  2127  cg25247290  2887  cg20100910  3647  cg01290568  4407  cg24605090  608  cg07160932  1368  cg16234557  2128  cg25257905  2888  cg20200460  3648  cg02596281  4408  cg25281616  609  cg07167946  1369  cg16234978  2129  cg25259564  2889  cg20275528  3649  cg07935264  4409  cg25437674  610  cg07180538  1370  cg16239482  2130  cg25260137  2890  cg20295992  3650  cg14117934  4410  cg25579157  611  cg07184578  1371  cg16252110  2131  cg25266629  2891  cg20311863  3651  cg15836722  4411  cg25821896  202224094 33 No.  DMP ID  No.  DMP ID  No.  DMP ID  No.  DMP ID  No.  DMP ID  No.  DMP ID  612  cg07203423  1372  cg16257051  2132  cg25267258  2892  cg20435725  3652  cg18635064  4412  cg25838645  613  cg07204280  1373  cg16279237  2133  cg25274503  2893  cg20453394  3653  cg18773937  4413  cg25852472  614  cg07204550  1374  cg16288089  2134  cg25299011  2894  cg20458740  3654  cg20157753  4414  cg26469586  615  cg07211212  1375  cg16313485  2135  cg25316663  2895  cg20536041  3655  cg23149881  4415  cg26808784  616  cg07212778  1376  cg16348470  2136  cg25324047  2896  cg20585530  3656  cg00688785  4416  cg26857192  617  cg07302069  1377  cg16364121  2137  cg25338036  2897  cg20628743  3657  cg02885007  4417  cg27300742  618  cg07333231  1378  cg16370398  2138  cg25339566  2898  cg20647610  3658  cg04730882  4418  cg02280281  619  cg07349208  1379  cg16384355  2139  cg25340966  2899  cg20704537  3659  cg08363794  4419  cg06266613  620  cg07351192  1380  cg16391955  2140  cg25370753  2900  cg20705938  3660  cg09173768  4420  cg09296407  621  cg07403258  1381  cg16399136  2141  cg25386676  2901  cg20707780  3661  cg09968620  4421  cg10543450  622  cg07413251  1382  cg16400350  2142  cg25397945  2902  cg20711812  3662  cg10753836  4422  cg11149930  623  cg07434271  1383  cg16400631  2143  cg25401594  2903  cg20764887  3663  cg10957151  4423  cg18250846  624  cg07438617  1384  cg16404371  2144  cg25459558  2904  cg20779964  3664  cg12969193  4424  cg19957905  625  cg07475178  1385  cg16405026  2145  cg25464921  2905  cg20785796  3665  cg13158481  4425  cg20599967  626  cg07489502  1386  cg16413428  2146  cg25528916  2906  cg20899329  3666  cg14236662  4426  cg26267388  627  cg07495363  1387  cg16419441  2147  cg25539045  2907  cg20945566  3667  cg14410016  4427  cg01155290  628  cg07517893  1388  cg16421411  2148  cg25547580  2908  cg20981848  3668  cg14991487  4428  cg02150988  629  cg07519235  1389  cg16422098  2149  cg25556905  2909  cg21054147  3669  cg15991405  4429  cg02466815  630  cg07533148  1390  cg16426482  2150  cg25570913  2910  cg21069019  3670  cg19373813  4430  cg02746725  631  cg07536847  1391  cg16452248  2151  cg25587069  2911  cg21077559  3671  cg23068499  4431  cg03152288  632  cg07536910  1392  cg16457786  2152  cg25594100  2912  cg21106486  3672  cg25829490  4432  cg03401519  633  cg07540103  1393  cg16459364  2153  cg25596297  2913  cg21127068  3673  cg00371702  4433  cg03450948  634  cg07560741  1394  cg16467854  2154  cg25622366  2914  cg21158087  3674  cg00758229  4434  cg03553278  635  cg07563611  1395  cg16476975  2155  cg25633678  2915  cg21179088  3675  cg00902374  4435  cg04003136  636  cg07573209  1396  cg16479539  2156  cg25660390  2916  cg21235151  3676  cg01794805  4436  cg05099387  637  cg07599133  1397  cg16493071  2157  cg25662463  2917  cg21279510  3677  cg02499249  4437  cg05871694  638  cg07614018  1398  cg16504626  2158  cg25670330  2918  cg21291134  3678  cg02746691  4438  cg06697536  639  cg07629454  1399  cg16509851  2159  cg25691167  2919  cg21350575  3679  cg03428864  4439  cg07797397  640  cg07631575  1400  cg16519587  2160  cg25694349  2920  cg21383487  3680  cg03481274  4440  cg08809260  641  cg07642043  1401  cg16529477  2161  cg25714865  2921  cg21410293  3681  cg03531687  4441  cg09355771  642  cg07676859  1402  cg16543094  2162  cg25720804  2922  cg21425842  3682  cg05556038  4442  cg10086659  643  cg07687119  1403  cg16556145  2163  cg25730685  2923  cg21449256  3683  cg05789881  4443  cg10305451  644  cg07697895  1404  cg16560389  2164  cg25737323  2924  cg21461649  3684  cg06705767  4444  cg10477905  645  cg07703401  1405  cg16560824  2165  cg25738714  2925  cg21463554  3685  cg06720425  4445  cg11418595  646  cg07703462  1406  cg16571983  2166  cg25740565  2926  cg21482621  3686  cg07405178  4446  cg12602409  647  cg07739205  1407  cg16580499  2167  cg25756435  2927  cg21485303  3687  cg10712623  4447  cg13044985  648  cg07770968  1408  cg16596604  2168  cg25763036  2928  cg21534423  3688  cg10754327  4448  cg13092806  649  cg07780095  1409  cg16616521  2169  cg25764899  2929  cg21588562  3689  cg11177552  4449  cg13768137  650  cg07780543  1410  cg16617795  2170  cg25774643  2930  cg21627409  3690  cg12479047  4450  cg14324370  651  cg07788369  1411  cg16620382  2171  cg25797887  2931  cg21660452  3691  cg15011775  4451  cg18987335  652  cg07790615  1412  cg16624692  2172  cg25830696  2932  cg21699044  3692  cg15607292  4452  cg19001226  653  cg07792478  1413  cg16635314  2173  cg25832771  2933  cg21718267  3693  cg16273366  4453  cg19335437  654  cg07795402  1414  cg16640855  2174  cg25863289  2934  cg21748244  3694  cg16927871  4454  cg19542816  655  cg07802350  1415  cg16657538  2175  cg25875213  2935  cg21771200  3695  cg18094781  4455  cg20676716  202224094 34 No.  DMP ID  No.  DMP ID  No.  DMP ID  No.  DMP ID  No.  DMP ID  No.  DMP ID  656  cg07808967  1416  cg16664405  2176  cg25881804  2936  cg21784917  3696  cg18651663  4456  cg22934308  657  cg07810282  1417  cg16665866  2177  cg25884711  2937  cg21865150  3697  cg19003815  4457  cg23322546  658  cg07834841  1418  cg16678111  2178  cg25888561  2938  cg21883598  3698  cg20899354  4458  cg23420260  659  cg07834955  1419  cg16703956  2179  cg25900085  2939  cg21899743  3699  cg20981919  4459  cg24154779  660  cg07835424  1420  cg16704797  2180  cg25902889  2940  cg21974506  3700  cg21646032  4460  cg25185585  661  cg07846220  1421  cg16705697  2181  cg25903779  2941  cg21977377  3701  cg21902772  4461  cg25347419  662  cg07860213  1422  cg16707405  2182  cg25908985  2942  cg22007163  3702  cg23518541  4462  cg26754761  663  cg07878486  1423  cg16708264  2183  cg25916282  2943  cg22037408  3703  cg24396624  4463  cg00790255  664  cg07881405  1424  cg16709232  2184  cg25916711  2944  cg22058708  3704  cg24833569  4464  cg02153814  665  cg07886472  1425  cg16729415  2185  cg25931491  2945  cg22130262  3705  cg25010415  4465  cg03765423  666  cg07907386  1426  cg16732616  2186  cg25942990  2946  cg22178238  3706  cg26124016  4466  cg07141504  667  cg07915921  1427  cg16755500  2187  cg25947490  2947  cg22263031  3707  cg26786980  4467  cg08991643  668  cg07921384  1428  cg16768018  2188  cg25950112  2948  cg22275864  3708  cg27486427  4468  cg10663765  669  cg07931391  1429  cg16771578  2189  cg25950625  2949  cg22348992  3709  cg27574595  4469  cg11324650  670  cg07931411  1430  cg16781647  2190  cg25951981  2950  cg22400703  3710  cg00599770  4470  cg12155036  671  cg07936950  1431  cg16783744  2191  cg25958283  2951  cg22550446  3711  cg01936839  4471  cg13335054  672  cg07951347  1432  cg16793866  2192  cg25970832  2952  cg22637867  3712  cg02000318  4472  cg15068180  673  cg07953015  1433  cg16823083  2193  cg25976440  2953  cg22678436  3713  cg02384857  4473  cg16924010  674  cg07959771  1434  cg16842053  2194  cg26001902  2954  cg22712883  3714  cg03232620  4474  cg18677603  675  cg07967632  1435  cg16857858  2195  cg26010877  2955  cg22740895  3715  cg05471296  4475  cg21916479  676  cg07973507  1436  cg16860971  2196  cg26026748  2956  cg22769941  3716  cg05743885  4476  cg25661792  677  cg07974511  1437  cg16865446  2197  cg26048630  2957  cg22809871  3717  cg06911354  4477  cg00079219  678  cg07976064  1438  cg16887264  2198  cg26079753  2958  cg22861116  3718  cg06934774  4478  cg00796424  679  cg07978472  1439  cg16896847  2199  cg26091021  2959  cg22885136  3719  cg08248516  4479  cg02384661  680  cg07984133  1440  cg16904330  2200  cg26107890  2960  cg22891500  3720  cg08396193  4480  cg02510471  681  cg07994987  1441  cg16924337  2201  cg26120093  2961  cg22946562  3721  cg08934785  4481  cg02665037  682  cg08012275  1442  cg16927040  2202  cg26125625  2962  cg22976218  3722  cg10474350  4482  cg03132556  683  cg08015388  1443  cg16963144  2203  cg26132320  2963  cg22982368  3723  cg11165752  4483  cg03536474  684  cg08034379  1444  cg16964348  2204  cg26132774  2964  cg23056713  3724  cg11910375  4484  cg03762366  685  cg08040429  1445  cg16966315  2205  cg26151206  2965  cg23075337  3725  cg12196573  4485  cg04203883  686  cg08047907  1446  cg16985778  2206  cg26158897  2966  cg23079252  3726  cg15372603  4486  cg05516489  687  cg08063051  1447  cg16987305  2207  cg26165993  2967  cg23141355  3727  cg15797110  4487  cg06622953  688  cg08065231  1448  cg16998150  2208  cg26170604  2968  cg23156916  3728  cg16764637  4488  cg06630413  689  cg08066035  1449  cg17025560  2209  cg26205771  2969  cg23217097  3729  cg17642941  4489  cg06708937  690  cg08089301  1450  cg17033333  2210  cg26210445  2970  cg23234149  3730  cg18436984  4490  cg06850442  691  cg08104202  1451  cg17037963  2211  cg26238975  2971  cg23240355  3731  cg18811550  4491  cg07035173  692  cg08111446  1452  cg17039236  2212  cg26248173  2972  cg23288059  3732  cg19147218  4492  cg07123069  693  cg08133327  1453  cg17059658  2213  cg26261793  2973  cg23316253  3733  cg19153763  4493  cg07697238  694  cg08146483  1454  cg17090954  2214  cg26281453  2974  cg23318812  3734  cg20293594  4494  cg08857479  695  cg08149193  1455  cg17101450  2215  cg26296488  2975  cg23424003  3735  cg20725013  4495  cg08962452  696  cg08151857  1456  cg17138769  2216  cg26299169  2976  cg23432345  3736  cg21778348  4496  cg10641615  697  cg08189989  1457  cg17162024  2217  cg26331172  2977  cg23521666  3737  cg22623133  4497  cg11328436  698  cg08190858  1458  cg17171215  2218  cg26345619  2978  cg23536473  3738  cg24389054  4498  cg12599390  699  cg08195943  1459  cg17202313  2219  cg26354493  2979  cg23586322  3739  cg25727671  4499  cg13855243  202224094 35 No.  DMP ID  No.  DMP ID  No.  DMP ID  No.  DMP ID  No.  DMP ID  No.  DMP ID  700  cg08244085  1460  cg17203063  2220  cg26359646  2980  cg23605961  3740  cg26511321  4500  cg14691529  701  cg08249988  1461  cg17208528  2221  cg26365299  2981  cg23642130  3741  cg27508551  4501  cg15731655  702  cg08263589  1462  cg17227967  2222  cg26371061  2982  cg23658477  3742  cg01572694  4502  cg15830509  703  cg08272731  1463  cg17228900  2223  cg26371320  2983  cg23660154  3743  cg02132714  4503  cg16006349  704  cg08273362  1464  cg17231999  2224  cg26429674  2984  cg23671221  3744  cg02422694  4504  cg17273416  705  cg08304190  1465  cg17239057  2225  cg26444528  2985  cg23856293  3745  cg04014328  4505  cg17573720  706  cg08305551  1466  cg17241776  2226  cg26452868  2986  cg23890008  3746  cg04514255  4506  cg18824990  707  cg08315202  1467  cg17247026  2227  cg26470101  2987  cg23891360  3747  cg04609859  4507  cg20116805  708  cg08322102  1468  cg17264670  2228  cg26476852  2988  cg23960736  3748  cg05527785  4508  cg22709192  709  cg08327269  1469  cg17279773  2229  cg26479667  2989  cg24021956  3749  cg07015911  4509  cg22829917  710  cg08335510  1470  cg17283169  2230  cg26491818  2990  cg24150623  3750  cg09194159  4510  cg23395715  711  cg08347500  1471  cg17284804  2231  cg26492446  2991  cg24161057  3751  cg10585948  4511  cg24895871  712  cg08358166  1472  cg17288397  2232  cg26519184  2992  cg24267283  3752  cg10953655  4512  cg26386624  713  cg08364561  1473  cg17294725  2233  cg26521404  2993  cg24331598  3753  cg11971423  4513  cg00314622  714  cg08368654  1474  cg17302155  2234  cg26537561  2994  cg24366168  3754  cg12806763  4514  cg02102424  715  cg08373573  1475  cg17305181  2235  cg26539736  2995  cg24366702  3755  cg13789775  4515  cg02647998  716  cg08382226  1476  cg17316316  2236  cg26560222  2996  cg24384244  3756  cg14345497  4516  cg02700894  717  cg08402365  1477  cg17319718  2237  cg26570179  2997  cg24416513  3757  cg14884929  4517  cg03310376  718  cg08406370  1478  cg17331296  2238  cg26618965  2998  cg24496475  3758  cg15649236  4518  cg05124441  719  cg08438705  1479  cg17334762  2239  cg26630231  2999  cg24496841  3759  cg17144149  4519  cg07357827  720  cg08440178  1480  cg17342973  2240  cg26635219  3000  cg24505892  3760  cg19081437  4520  cg08541642  721  cg08443563  1481  cg17349389  2241  cg26673012  3001  cg24545495  3761  cg19710451  4521  cg10110335  722  cg08448701  1482  cg17364913  2242  cg26678605  3002  cg24554839  3762  cg20693334  4522  cg10173186  723  cg08464190  1483  cg17373442  2243  cg26682580  3003  cg24570303  3763  cg21460081  4523  cg10245988  724  cg08480826  1484  cg17380661  2244  cg26701408  3004  cg24586870  3764  cg22660147  4524  cg10958002  725  cg08481075  1485  cg17384889  2245  cg26714388  3005  cg24631482  3765  cg24114154  4525  cg14691921  726  cg08482501  1486  cg17386213  2246  cg26718232  3006  cg24632241  3766  cg25145670  4526  cg14843337  727  cg08483912  1487  cg17395064  2247  cg26718878  3007  cg24637364  3767  cg26072749  4527  cg15695478  728  cg08490115  1488  cg17401179  2248  cg26730416  3008  cg24663256  3768  cg26916621  4528  cg15873301  729  cg08495115  1489  cg17410236  2249  cg26733301  3009  cg24686074  3769  cg27496615  4529  cg16791134  730  cg08516516  1490  cg17437939  2250  cg26765743  3010  cg24705960  3770  cg00072689  4530  cg16858253  731  cg08530237  1491  cg17463633  2251  cg26783057  3011  cg24722073  3771  cg01324550  4531  cg20888142  732  cg08548396  1492  cg17466857  2252  cg26809635  3012  cg24740576  3772  cg01723934  4532  cg22839075  733  cg08553437  1493  cg17480760  2253  cg26818625  3013  cg24748769  3773  cg01986016  4533  cg23769143  734  cg08566455  1494  cg17485838  2254  cg26824006  3014  cg24847685  3774  cg02086493  4534  cg25982743  735  cg08572611  1495  cg17498296  2255  cg26831119  3015  cg24856726  3775  cg02566861  4535  cg26655299  736  cg08575330  1496  cg17504999  2256  cg26839871  3016  cg24896649  3776  cg02574073  4536  cg01185801  737  cg08594218  1497  cg17508991  2257  cg26840068  3017  cg24932585  3777  cg03803541  4537  cg02943285  738  cg08604097  1498  cg17510385  2258  cg26848718  3018  cg24961583  3778  cg04435975  4538  cg04073608  739  cg08607018  1499  cg17520909  2259  cg26859593  3019  cg25208017  3779  cg05332887  4539  cg04378603  740  cg08610862  1500  cg17526573  2260  cg26860935  3020  cg25288420  3780  cg05490023  4540  cg04868132  741  cg08620044  1501  cg17535595  2261  cg26864714  3021  cg25317585  3781  cg05888755  4541  cg04977124  742  cg08640634  1502  cg17538572  2262  cg26890189  3022  cg25423004  3782  cg07318128  4542  cg05491695  743  cg08680048  1503  cg17542408  2263  cg26923490  3023  cg25460281  3783  cg07676709  4543  cg07799005  202224094 36 No.  DMP ID  No.  DMP ID  No.  DMP ID  No.  DMP ID  No.  DMP ID  No.  DMP ID  744  cg08701047  1504  cg17550009  2264  cg26931862  3024  cg25503903  3784  cg08832695  4544  cg10631284  745  cg08708684  1505  cg17555825  2265  cg26983177  3025  cg25514273  3785  cg09601584  4545  cg12498916  746  cg08722200  1506  cg17567560  2266  cg26990102  3026  cg25517810  3786  cg09983216  4546  cg14690315  747  cg08725319  1507  cg17651959  2267  cg26990587  3027  cg25542878  3787  cg10906729  4547  cg15574972  748  cg08732352  1508  cg17696563  2268  cg26997553  3028  cg25588480  3788  cg11352083  4548  cg17153055  749  cg08758174  1509  cg17698295  2269  cg27014380  3029  cg25678815  3789  cg11850549  4549  cg18501142  750  cg08774368  1510  cg17712694  2270  cg27030541  3030  cg25707722  3790  cg14509967  4550  cg19878733  751  cg08800878  1511  cg17721710  2271  cg27032232  3031  cg25732462  3791  cg15435170  4551  cg20503416  752  cg08803500  1512  cg17723653  2272  cg27046920  3032  cg25742246  3792  cg15908709  4552  cg22311458  753  cg08815340  1513  cg17736443  2273  cg27049766  3033  cg25763393  3793  cg16848873  4553  cg23566411  754  cg08822897  1514  cg17754510  2274  cg27071152  3034  cg25825488  3794  cg17179862  4554  cg26489875  755  cg08832906  1515  cg17760049  2275  cg27083087  3035  cg25830182  3795  cg18684142  4555  cg00051623  756  cg08833577  1516  cg17774559  2276  cg27085741  3036  cg25832274  3796  cg18878432  4556  cg0777802  757  cg08850461  1517  cg17812788  2277  cg27089768  3037  cg25946059  3797  cg19828220      758  cg08862890  1518  cg17816394  2278  cg27104173  3038  cg25947489  3798  cg20471691      759  cg08864283  1519  cg17820890  2279  cg27109129  3039  cg25948031  3799  cg20591728      760  cg08876932  1520  cg17840719  2280  cg27116912  3040  cg25950325  3800  cg21387752      The DMPs mentioned in Table 1 are provided in the Illumina ID nomenclature. Information on the genomic location of the methylation sites, as well as data on associated experiments, studies and scientific references etc. can be derived, for example, from the website of Illumina (www.illumina.com). Accordingly, the identity of each DMP represented by each DMP loci identifier as depicted in Table 1 is publicly available from the Illumina website, e.g., under reference to the DMP sites used in the Infinium HumanMethylation450 BeadChip kit. A complete reference to genomic sequences and positions corresponding to the Illumina IDs as depicted in Table 1 can be downloaded at https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GPL13534 in the supplementary file section where, in particular at https://www.ncbi.nlm.nih.gov/geo/download/?acc=GPL13534&forma t=file&file=GPL13534%5FHumanMethylation450%5F15017482%5Fv%2E1 %2E1%2Ecsv%2Egz; or https://www.ncbi.nlm.nih.gov/geo/download/?acc=GPL13534&forma t=file&file=GPL13534%5FHumanMethylation450%5F15017482%5Fv%2E1 %2E1%2Ecsv%2Egz, 202224094 37 complete datasets are provided. Alternatively, such references may be downloaded at https://webdata.illumina.com/downloads/ productfiles/humanmethylation450/humanmethylation450_15017482 _v1-2.csv. As further alternative, a genome browser such as, for example, the genome browser of USCS (http://genome- euro.ucsc.edu/), which provides a graphic scheme of the genomic location including additional information on the encoded sequences etc. can be used to derive molecular and positioning information on most DMP loci identifier as depicted in Table 1. For instance, upon introducing the DMP's Illumina ID as shown in Table 1 (cg…) into the genome browser coordinates of the genomic location of the DMP can be retrieved. Coordinates of genomic location of the DMPs may accordingly be used for the design and synthesis of adjacent or binding polynucleotides, e.g., primer sequences, or for sequence analysis purposes etc. The Illumina ID nomenclature is constructed on CG loci designation which is based on actual or contextual sequences of each CpG locus and takes advantage of the sequences flanking the DMP. Thereby the ID is unaffected by reference genome changes or differences in genome versions. This allows for an unambiguous assignment of the ID to genomic coordinates. Further the Illumina Infinium HumanMethylation450 BeadChip array system (or any future and functionally equivalent variant thereof) may be used to further analyze or assess any of the DMPs shown in Table 1. The combination of polynucleotides according to the present invention is for the enrichment and/or detection of the panel of at least 4500 methylation sites as defined above in a 202224094 38 sample comprising human DNA for cancer screening, i.e., it allows to select or enrich DNA molecules, e.g., DNA sample fragments and analyze them with respect to the presence of methylated CpG sites, indicating the presence of a cancer disease or a predisposition for a cancer disease, preferably of lung or breast cancer. For selecting or enriching DNA molecules from a human DNA sample said combination of polynucleotides representing the CpG sites and adjacent sectors are used. The combination of polynucleotides is represented by nucleotide sequences in the human DNA. The polynucleotides may be primers and/or probes designed to hybridize to said nucleotide sequences in the human DNA allowing for the enrichment and/or detection of said methylation sites. The term "represented by nucleotide sequences" as used herein means that the DMP itself is localized or embedded in a genomic context in the form of adjacent sequences at the 5' and 3' end. These contextual sequences, together with the genomic coordinate, represent the methylation site and allow for the provision of complementary polynucleotides, e.g., in the form of polynucleotide probes. These complementary polynucleotides or polynucleotide probes may, for example, be capable of hybridizing to the nucleotide sequence representing the DMP. In certain embodiments, complementary polynucleotides may be capable of hybridizing not only to contextual sequences of one DMP, but also to such sequences of two or more DMPs, e.g., in case DMPs are located in close vicinity. In certain embodiments the complementary polynucleotides are primers and/or probes and may be used for enrichment procedures and/or detection of said methylation sites, e.g., 202224094 39 by allowing for a binding or hybridization with a human DNA molecule from a target subject's or patient's sample. The term "subject" as used herein refers to several different groups of individuals such as a healthy individual that is not suspected of having a pre-invasive lesion, a pre- cancerous cell or a cancer disease; or an individual that is suspected of having a pre-invasive lesion or a pre-cancerous cell; or an individual, that has a pre-invasive lesion or a pre-cancerous cell population but is not suspected of having a cancer disease; or an individual that has a pre-invasive lesion or a pre-cancerous cell population and is suspected of having a cancer disease; or an individual that is suspected of having a pre-invasive lesion or a pre-cancerous cell population; or an individual that has a pre-invasive lesion or a pre-cancerous cell population; or an individual that is suspected of having a cancer disease; or an individual that has a cancer disease. A "target subject" is any subject as defined above, for which an analysis based on the methods described herein is considered suitable, diagnostically useful, or necessary. The term "patient" as used herein is meant to relate to a sub-group of the subjects as defined herein, i.e., an individual that has a pre-invasive lesion or a pre-cancerous cell population; or an individual that is afflicted by a cancer disease. In principle, the enrichment is based on a hybridization of the combination of polynucleotides according to the present invention, e.g. primers and/or probes to the human DNA molecule from a target subject's or patient's sample and a subsequent pull-down of the DNA molecules which are considered to be informative for the determination of the presence of a cancer disease due to the differential methylation status of CpG sites in the DNA molecule. The term 202224094 40 "complementary polynucleotide" as used herein includes both sense and antisense directions. Also, a mixture of polynucleotides for both strands is envisaged. In principle, the human DNA molecule to be enriched may be a non-modified DNA molecule or a modified DNA molecule, e.g., as described herein, preferably a DNA molecule which has been bisulfite- converted or enzymatically converted. The combination of polynucleotides, e.g. primers and/or probes, may, in certain embodiments, be linked or tethered to a solid support such as an array structure or the like. Also, a link, e.g., via biotin-streptavidin interaction, with magnetic beads and a corresponding actuation and fixation by magnetic forces is envisaged. In further embodiments the combination of polynucleotides may be provided in the form of a solid-phase reagent or as a solid phase means, or a set of such means. The solid-phase reagent or means may accordingly comprise the polynucleotides as defined herein bound to a solid phase. In specific embodiments, the solid phase may be or comprise a particle or set of particles or be associated to or presented as an array. The polynucleotides may have any suitable length. Preferably, they comprise 50 to 150 nucleotides, e.g., 50, 60, 70, 80, 90, 100, 110, 120, 130, 140 or 150 nucleotides, or any value in between the mentioned values. In particularly preferred embodiments, they have a length of about 120 nucleotides. It is further preferred that the polynucleotides are designed to hybridize to human DNA molecules comprising more than one DMP, e.g., two or three or more. For example, the polynucleotides may be designed to cover an optimized amount of DMPs as shown in Table 1. In a particularly preferred embodiment, at least 4500 DMPs or the entire set of DMPs of Table 1 may be represented by a number of about 3000, 4000 or 202224094 41 4500 polynucleotides, or any other suitable number. The present invention also envisages a lower number of probes, e.g., if more than one DMP is covered by a polynucleotide. Also envisaged is a higher number of oligonucleotides, e.g., if a different target coverage is intended, or if additional DMPs not mentioned in Table 1 are further included. In certain embodiments the present invention also envisages the use of a panel as defined herein, preferably a panel comprising the DMPs of Table 1 or at least 4500 DMPs thereof, for the selection, provision, design, synthesis and/or modification of a combination of complementary polynucleotides as defined herein. According to the present invention the human DNA molecule for subsequent analysis, in particular enrichment, may be derived from a target subject's or patient's sample. The sample may be any suitable sample type or form. The sample may, for example, have been obtained from a subject or group of subjects. In certain embodiments, the sample is a tumor sample, i.e., the nucleic acids may be extracted from a tumor of a subject, in other embodiments the sample may be a tissue, e.g., tissue biopsy, urine, blood, semen, liquor, plasma, serum or other sample. Particularly preferred are liquid biopsy samples derived from blood/urine or other body fluids or tissue biopsy samples. Also envisaged is to make use of previously deposited samples. It is particularly preferred that the sample is a cell free DNA (cfDNA) sample. The term "cfDNA" as used herein refers to degraded DNA fragments released to body fluids such as blood plasma, urine, cerebrospinal fluid, etc., wherein the cfDNA typically has a short half-life and requires rapid processing and/or stabilization. The typical size of cfDNA fragments is about 165 bp. cfDNA comprises various forms of DNA freely 202224094 42 circulating in body fluids such as circulating tumor DNA (ctDNA) or cell-free mitochondrial DNA (cf mtDNA). The use of cfDNA is particularly advantageous since elevated levels of cfDNA are observed in cancer, especially in advanced disease stages. In further preferred embodiments the sample is a genomic human DNA molecule sample, which can be derived, e.g., from a tissue obtained in a biopsy. In a further aspect the present invention relates to a method of enriching DNA molecules derived from a subject’s sample, e.g., as described above comprising: (a) modifying the DNA molecules to allow for determination of the methylation status of methylation sites; (b) contacting the converted molecules, i.e. the bisulfite-converted or enzymatically converted molecules, with a combination of polynucleotides as described herein and enriching bisulfite-converted or enzymatically converted DNA molecules by hybridization capture. The "modification of DNA molecules" may be based on any technology, which allows for the determination of the methylation status of methylation sites. It is preferred that the modification is a bisulfite-conversion or enzymatic conversion as described in detail herein. The "contacting" of correspondingly modified DNA molecules with polynucleotides is to be understood as binding or hybridization reaction with complementary sequences, preferably polynucleotide probes as described herein. The binding is a sequence-specific hybridization, which allows to specifically collect only DNA molecules which show a high degree of complementarity with the polynucleotides, e.g., 95%, 96%, 97%, 98%, 99%, 100%. The binding specificity may be adjusted by changes to the hybridization conditions, e.g., temperature, pH, ionic concentrations etc. The polynucleotides may have any suitable length, preferably a length of 50–150 nucleotides, more preferably of 120 nucleotides. The polynucleotides may be 202224094 43 free floating or be tethered or linked to a support, e.g., as described herein in detail, to allow for pulling down binding DNA molecules. Also, the alternative use of magnetic beads and a corresponding magnetic actuation approach is envisaged. Further contemplated are antibody-based techniques, as well as molecular approaches based on biotin/streptavidin interactions. Subsequent to the contacting step, the bound DNA molecules are "enriched", i.e., only DNA molecules which are in fact specifically bound to the polynucleotide probes are kept or retained, whereas other, non-bound or not specifically bound DNA molecules or other components in a mixture are discarded. The enriched DNA molecules may be used for further analysis steps or stored for future activities. Enriched DNA molecules may, in additional embodiments, further be amplified. Also contemplated is a spiking with specific indices that allow for a sequencing of the molecules. As a further step, which may be optional, the method comprises a step of determining the sequence of the enriched molecule. The sequence data of the enriched and optionally previously modified DNA molecules may be obtained with any suitable technology, preferably in a high-throughput approach. This typically includes next-generation sequence (NGS) or second-generation sequencing techniques. Such approaches comprise any sequencing method that determines the nucleotide sequence of either individual nucleic acid molecules or expanded clones for individual nucleic acid molecules in a highly parallel fashion. The sequencing may be performed according to any suitable massive parallel approach. Typical platforms include Illumina, Life Technologies Ion Proton, Oxford Nanopore Technologies, Pac Bio, Complete Genomics/BGI, Ultima, Element Biosciences, 202224094 44 Singular Genomics, GeneReader, GenapSys, Solexa, Solid or Helicos Biosciences Heliscope systems. In certain embodiments, the sequencing may include a previous preparation of nucleic acids, the sequencing, as well as subsequent imaging and initial data analysis steps. Preparation steps may, for example, include amplification steps, e.g., PCR amplification, randomly breaking nucleic acids into smaller sizes and generating sequencing templates such as fragment templates. Spatially separated templates can, for example, be attached or immobilized at solid surfaces which allows for multiple sequencing reactions to be performed simultaneously. In typical examples, a library of nucleic acid fragments may be generated and adaptors containing universal priming sites may be ligated to the end of the fragments. Subsequently, the fragments can be denatured into single strands and captured by beads. Suitable sequencing methods include, but are not limited to, cyclic reversible termination (CRT) or sequencing by synthesis (SBS) by Illumina, sequencing by ligation (SBL), single-molecule addition (pyrosequencing) or real-time sequencing. Exemplary platforms using CRT methods are Illumina/Solexa and HelicoScope. Exemplary SBL platforms include the Life/APG/SOLiD support oligonucleotide ligation detection. An exemplary pyrosequencing platform is Roche/454. Exemplary real-time sequencing platforms include the Pacific Biosciences platform and the Life/Visi-Gen platform. Other sequencing methods to obtain massively parallel nucleic acid sequence data include nanopore sequencing, sequencing by hybridization, nano-transistor array-based sequencing, scanning tunneling microscopy (STM) based sequencing, or nanowire-molecule sensor-based sequencing. Further details with respect to the sequencing approach would be known to the skilled person or can be derived from suitable literature 202224094 45 sources such as Goodwin et al., Nature Reviews Genetics, 2016, 17, 333-351, or van Dijk et al., Trends in Genetics, 2014, 9, 418-426. Correspondingly obtained data are provided in the form of sequencing reads which may be single-end or paired-end reads. Obtaining such sequencing data may further include the addition of assessment steps or data analysis steps. Furthermore, the presently described methodology may be used with any suitable sequencing read length. It is preferred to make use of sequencing reads of a length of about 50 to about 170, e.g., 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170 or more nucleotides or any value in between the mentioned values. Particularly preferred is paired end sequencing with 2 x 75 bp reads or with 2 x 150 bp reads. The obtained sequence data may further be assembled into contigs or suitable subsections thereof, e.g., on the basis of chromosomes, chromosome portions etc., and/or be aligned to a reference sequence, e.g., an annotated genomic sequence. In certain embodiments the alignment and comparison step further includes a reference searching step of literature knowledge concerning identified mutations or aberrations as well as associated cancer diagnostic information. The elucidation of the sequence of the enriched DNA molecules further allows to determine the methylation status of the enriched molecule. For example, as described above, in the DNA sequencing, uracil, which is turned to thymine during amplification, is recognized as thymine during sequencing and on the opposite strand adenine is provided due to base pairing, while methylated cytidines are paired with guanines. C->U transitions at the unmethylated sites can accordingly be 202224094 46 detected, e.g., by comparing the sequences with reference sequences or, for example, parallel sequencing results with enriched non-bisulfite converted or non-enzymatic converted DNA molecules. Accordingly, in certain embodiments, the present invention envisages a double or parallel approach wherein DNA molecules from a sample are (i) modified by the bisulfite or enzymatic conversion; and (e.g., a portion of the sample) (ii) are not modified. Both groups of molecules are subsequently enriched and analyzed as described above, e.g., by determining the sequence. Finally, a comparison of both sequences may be performed to detect methylated positions. This may further be compared with sequences stored in databases comprising information on said DMPs or CpG- sites. Examples of suitable databases include KEGG (Kanehisa and Goto, 2000, Nucleic Acids Research, 28, 1, 27-30), GO (Gene Ontology Consortium, 2004, Nucleic Acids Research, 32, Suppl 1, D258-D261) and CanMethdb (Zhao et al., 2023, Bioinformatics, 39, 1, btac783). In yet another aspect the present invention relates to a method of diagnosing, prognosing or predicting a cancer disease in a subject. The method comprises a step of enriching DNA molecules derived from the subject’s sample and determining the sequence and methylation status of the enriched DNA molecules. The enrichment is preferably performed according to the methods as described herein. In particular a target subject's sample is obtained, or such a sample is used for enrichment, preferably using the combination of polynucleotides as described herein. Subsequently, the sequence and/or methylation status of the enriched DNA molecules is determined, as described herein. 202224094 47 In a next step the obtained sequence information and methylation status information is analyzed. This is preferably done with the help of or by using a database comprising information on cancer related methylation states. It is particularly preferred to use bioinformatic analysis procedures. Further information can be derived from suitable literature references such as Zhao et al., 2023, Bioinformatics, 39, 1, btac783. Finally, a diagnostic, prognostic and/or predictive conclusion with respect to the presence of a cancer disease in the subject is derived. The term "diagnostic, prognostic and/or predictive conclusion" as used herein refers to information on medical or therapeutic consequences of non- normal methylation pattern detected in the analyzed DNA molecules. For example, if a certain methylation status of a DMP, preferably of a multitude of DMPs, covered by a DNA molecule or a group of DNA molecules or the majority of DNA molecules, preferably of enriched DNA molecules of a target subject's sample is identified which is connected to cancer training samples, e.g., a lung or breast cancer training sample, this connection or link may be translated into a diagnostic output, e.g. a classification as carcinogenic, preferably for lung or breast cancer. Similarly, if certain non-normal methylation patterns are detected which are connected to early symptoms of a cancer disease this connection or link may be translated into a prognostic output, e.g., reflected by a classification as potentially carcinogenic or carcinogenic in an early stage or the like, e.g., early-stage lung or breast cancer. Also, should certain non-normal methylation patterns be detected which are connected to therapeutic suggestions or 202224094 48 instructions in the context of a cancer disease, preferably lung or breast cancer, this connection or link may be translated into a predictive output, e.g., reflected by a corresponding classification. Corresponding information may, for example, be derived from suitable literature sources or database entries associated with the DNA methylation data and therapeutic suggestions or options. In a preferred embodiment the diagnostic, prognostic and/or predictive conclusion with respect to the presence of a cancer disease in the subject may additionally be based on further data. Such further data may, for example, be the subject’s imaging-based data. Examples of contemplated imaging-based data are mammography analysis data, ultra-low- dose CT screening data, medical images and/or pathology images. These data, which preferably are themselves already connected to or translated into a diagnostic, prognostic or predictive output may be offset or combined with the conclusions derived from the differential methylation analysis. These data may in principle be combined with conclusions and other data entities via multimodal data integration. Typically, the integration may be performed as early, intermediate or late fusion. The present invention preferably contemplates a late fusion in which, for example, a methylation-based score is combined with an imaging-based score, e.g., using a logistic regression. Also envisaged are early and intermediate fusion approaches. In a specific embodiment the combination of input data may, based on suitable weighing algorithms, result in an overall diagnostic, prognostic and/or predictive conclusion. In the alternative or in addition, i.e., in a further preferred embodiment the diagnostic, prognostic and/or predictive conclusion with respect to the presence of a 202224094 49 cancer disease in the subject may additionally be founded on non-imaging-based data. Examples of contemplated non-imaging- based data are data on age, sex, race, characteristics of cancer phenotype, histologic characteristics, stage of development of cancer, histologic subtype, detectable molecular changes, preferably on the level of the genome, transcriptome, metabolome, proteome, glycome or lipidome, biomarkers and/or laboratory tests. These data may be offset or combined with the conclusions derived from the differential methylation analysis and optionally with the conclusions including the imaging-based data. These data may in principle be combined with conclusions and other data entities via multimodal data integration as defined herein above. In specific embodiments, the combination input data may, based on suitable weighing algorithms, result in a further, more complete overall diagnostic, prognostic and/or predictive conclusion. Corresponding information, e.g., regarding the influence of these factors on disease manifestations etc. may, for example, be derived from suitable literature sources or database entries associated with the methylation data, e.g., non-normal methylation patterns.

Claims

202224094 50 CLAIMS 1. A combination of polynucleotides for the enrichment and/or detection of a panel of at least 4500 methylation sites in a sample comprising human DNA for cancer screening, wherein the methylation sites show a non-normal methylation pattern in at least one cancer training sample. 2. The combination of polynucleotides of claim 1, wherein said methylation sites are represented by nucleotide sequences in the human DNA and the polynucleotides are primers and/or probes designed to hybridize to said nucleotide sequences in the human DNA allowing for the enrichment and/or detection of said methylation sites. 3. The combination of polynucleotides of claim 1 or 2, wherein said non-normal methylation pattern is a differential methylation pattern, wherein methylated and/or unmethylated sites are present in a cancer training sample in comparison to a healthy sample. 4. The combination of polynucleotides of claim 3, wherein the healthy sample is a tissue sample, preferably an FFPE tissue sample, spatially adjacent to the cancer training sample. 5. The combination of polynucleotides of claim 3 or 4, wherein said differential methylation pattern is present at a CpG site. 6. The combination of polynucleotides of any one of claims 1 to 5, wherein each polynucleotide has a 202224094 51 length of about 50 to 150 nucleotides, preferably of about 120 nucleotides. 7. The combination of polynucleotides of any one of claims 2 to 6, wherein the sample comprising human DNA is a liquid biopsy sample or a tissue biopsy sample, wherein the human DNA is preferably a cfDNA molecule or a genomic DNA molecule. 8. The combination of polynucleotides of any one of claims 1 to 7, wherein the methylation sites are located in or cover a multitude of genomic regions, preferably genomic regions wherein a non-normal methylation pattern in at least one cancer training sample is present. 9. The combination of polynucleotides of any one of claims 1 to 8, wherein the methylation sites show a non-normal methylation pattern in at least one breast or lung cancer training sample. 10. The combination of polynucleotides of any one of claims 2 to 9, wherein one or more primers and/or probes are designed to cover one or more methylation sites. 11. The combination of polynucleotides of any one of claims 1 to 10, wherein the polynucleotides are designed to enrich and/or detect at least 4500 differentially methylated positions (DMPs) selected from Table 1. 202224094 52 12. A method of enriching DNA molecules derived from a subject’s sample, preferably a liquid biopsy or tissue biopsy sample, comprising: (a) modifying the DNA molecules to allow for determination of the methylation status of methylation sites, preferably by bisulfite-conversion or enzymatic conversion; and (b) contacting the converted molecules with a combination of polynucleotides selected from the combinations of polynucleotides as defined in any one of claims 1 to 11 and enriching bisulfite-converted or enzymatically converted DNA molecules by hybridization capture. 13. The method of claim 12, additionally comprising the step (c) of determining the sequence of the enriched molecules, thereby also determining the methylation status of the enriched molecules. 14. A method of diagnosing, prognosing or predicting a cancer disease in a subject, comprising: (a) enriching DNA molecules derived from the subject’s sample; and determining the sequence and methylation status of the enriched DNA molecules, preferably according to the method of claim 13; (b) assessing the obtained sequence information, preferably on the basis of a database comprising information on cancer related methylation states, more preferably via a bioinformatic analysis; and (c) deriving a diagnostic, prognostic and/or predictive conclusion with respect to the presence of a cancer disease in the subject. 202224094 53 15. The method of claim 14, additionally comprising the step of evaluation of (i) the subject’s imaging-based data, preferably derived from a mammography analysis, an ultra-low-dose CT screening, medical images and/or pathology images; and/or (ii) non-imaging-based data, such as data on age, sex, race, characteristics of cancer phenotype, histologic characteristics, stage of development of cancer, histologic subtype, detectable molecular changes, preferably on the level of the genome, transcriptome, metabolome, proteome, glycome or lipidome, biomarkers and/or laboratory tests, wherein the results of the evaluation(s) contribute to the diagnostic, prognostic and/or predictive conclusion with respect to the presence of a cancer disease in the subject.
PCT/EP2024/071082 2023-07-31 2024-07-25 Methylation panel for cancer screening Pending WO2025026857A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP23188626.8 2023-07-31
EP23188626 2023-07-31

Publications (1)

Publication Number Publication Date
WO2025026857A1 true WO2025026857A1 (en) 2025-02-06

Family

ID=87551228

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2024/071082 Pending WO2025026857A1 (en) 2023-07-31 2024-07-25 Methylation panel for cancer screening

Country Status (1)

Country Link
WO (1) WO2025026857A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019195268A2 (en) * 2018-04-02 2019-10-10 Grail, Inc. Methylation markers and targeted methylation probe panels

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019195268A2 (en) * 2018-04-02 2019-10-10 Grail, Inc. Methylation markers and targeted methylation probe panels

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
"Gene Ontology Consortium", NUCLEIC ACIDS RESEARCH, 2004, pages 32
BUCKLEY DAVID N ET AL: "Targeted DNA methylation from cell-free DNA using hybridization probe capture", NAR GENOMICS AND BIOINFORMATICS, vol. 4, no. 4, 31 December 2022 (2022-12-31), XP093214328, ISSN: 2631-9268, Retrieved from the Internet <URL:https://academic.oup.com/nargab/article/4/4/lqac099/6965981?login=true> DOI: 10.1093/nargab/lqac099 *
CHEN ET AL., CLIN EPIGENETICS, vol. 12, no. 1, 2020, pages 39
GOODWIN ET AL., NATURE REVIEWS GENETICS, vol. 17, 2016, pages 333 - 351
HO ET AL., JAMA NETW OPEN, vol. 5, no. 3, 2022, pages 222440
HOADLEY ET AL., CELL, vol. 173, no. 2, pages 291 - 304
KANEHISAGOTO, NUCLEIC ACIDS RESEARCH, vol. 28, no. 1, 2000, pages 27 - 30
LEBERG ET AL., BREAST CANCER RESEARCH, vol. 17, 2015, pages 63
LIU ET AL., ANNALS OF ONCOLOGY; 2020, vol. 31, no. 6, 2020, pages 745 - 759
STAHEL ET AL., EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY; THORACIC TUMOURS - ESSENTIALS FOR CLINICIANS, 2019
VAN DIJK ET AL., TRENDS IN GENETICS, vol. 9, 2014, pages 418 - 426
WU XIANRUI ET AL: "A novel cell-free DNA methylation-based model improves the early detection of colorectal cancer", MOLECULAR ONCOLOGY, vol. 15, no. 10, 1 October 2021 (2021-10-01), pages 2702 - 2714, XP093214331, ISSN: 1574-7891, Retrieved from the Internet <URL:https://febs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/1878-0261.12942> DOI: 10.1002/1878-0261.12942 *
ZHAO ET AL., BIOINFORMATICS, vol. 39, no. 1, 2023, pages btac783

Similar Documents

Publication Publication Date Title
Rahat et al. Circulating cell-free nucleic acids as epigenetic biomarkers in precision medicine
Ooi et al. Epigenomic profiling of primary gastric adenocarcinoma reveals super-enhancer heterogeneity
US11384401B2 (en) Detecting gastrointestinal neoplasms
CN113811622B (en) Detection of pancreatic ductal adenocarcinoma in plasma
CN103797120B (en) Biomarkers, therapeutic targets and uses of prostate cancer
CN102311953B (en) Method and kit for diagnosing bladder cancer with urine
US20140274767A1 (en) Dna methylation markers for metastatic prostate cancer
CN108779487A (en) Nucleic acid for detecting methylation state and method
TW201805429A (en) Using cell-free DNA fragment size to determine copy number variations
JP7665659B2 (en) Multimodal analysis of circulating tumor nucleic acid molecules
CN104846073B (en) The biological markers of prostate cancer, therapy target and application thereof
US20080274909A1 (en) Kits and Reagents for Use in Diagnosis and Prognosis of Genomic Disorders
CN121335988A (en) Non-invasive in vitro diagnostic methods
WO2025026857A1 (en) Methylation panel for cancer screening
WO2023226939A1 (en) Methylation biomarker for detecting colorectal cancer lymph node metastasis and use thereof
JP2024519082A (en) DNA methylation biomarkers for hepatocellular carcinoma
US20250006375A1 (en) Cancer detection and classification using methylome analysis
US20250357009A1 (en) Multi-tiered testing for tracking disease heterogeneity
KR20260011756A (en) Noninvasive in vitro diagnostic methods
WO2024192294A1 (en) Methods and systems for generating sequencing libraries
WO2024211731A1 (en) Arrays targeting differentially accessible chromatin regions using quantitative polymerase chain reaction
CN115772566A (en) Methylation biomarker for auxiliary detection of lung cancer somatic cell ERBB2 gene mutation and application thereof
WO2025210049A1 (en) Dna methylation marker for determination of t-status of cancer
WO2025251032A1 (en) Liver cancer methylation markers and machine models
KR20260011755A (en) Noninvasive in vitro method for detecting somatic mutations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24754574

Country of ref document: EP

Kind code of ref document: A1